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In order to obtain novel pharmacological tools and to investigate a multitargeting analgesic strategy, the
CB1 and CB2 cannabinoid receptor agonist JWH-018 was conjugated with the opiate analgesic oxycodone
or with an enkephalin related tetrapeptide. The opioid and cannabinoid pharmacophores were coupled
via spacers of different length and chemical structure. In vitro radioligand binding experiments
conﬁrmed that the resulting bivalent compounds bound both to the opioid and to the cannabinoid re-
ceptors with moderate to high afﬁnity. The highest afﬁnity bivalent derivatives 11 and 19 exhibited
agonist properties in [35S]GTPgS binding assays. These compounds activated MOR and CB (11mainly CB2,
whereas 19 mainly CB1) receptor-mediated signaling, as it was revealed by experiments using receptor
speciﬁc antagonists. In rats both 11 and 19 exhibited antiallodynic effect similar to the parent drugs in
20 mg dose at spinal level. These results support the strategy of multitargeting G-protein coupled re-
ceptors to develop lead compounds with antinociceptive properties.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Mu opioid receptor (MOR) agonists are the most common
therapeutics in clinic to alleviate severe pain. However, their dose-
limiting adverse effects inspire the development of novel analgesics
[1]. Cannabinoid (CB) receptor agonists can modulate hyperalgesiaBiology, Biological Research
vari krt. 62., H-6726, Szeged,
e of Medicine, Department of
e., Tucson, AZ 85724-5050.
served.and show effective therapeutic value against inﬂammatory and
chronic pain including neuropathic pain [2]. The co-administration
of MOR and CB receptor agonists has been shown to enhance the
antinociceptive effect with decreased opiate-related side-effects,
and the synergism of opioid and cannabinoid ligands has been
extensively studied [3] in mice [4e11], in rats [12e15], in rhesus
monkeys [16e19] and in an experimental pain model applied to
volunteers [20].
Initiated by the possible dimerization interaction of the opioid
and cannabinoid receptors [21e23] bivalent compounds, i.e. spacer
linked pharmacophores, were also considered to decrease the
opioid side-effects. Conjugating the MOR agonist fentanyl to the
CB1 antagonist/inverse agonist rimonabant resulted in MOR-CB
Abbreviations
ACN acetonitrile
AM 251 N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide
AM 630 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-
indol-3-yl](4-methoxyphenyl)methanone
BBB blood-brain barrier
Boc tert-butyloxycarbonyl
BSA bovine serum albumin
CB cannabinoid
DAMGO H-Tyr-D-Ala-Gly-N-MePhe-Gly-ol
DCM dichloromethane
DIC N,N0-diisopropylcarbodiimide
DIEA diisopropylethylamine
DMF dimethylformamide
DOR delta opioid receptor
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EtOAc ethyl acetate
EtOH ethanol
GPCR G-protein-coupled receptor
GTPgS guanosine 50-O-(3-thiotriphosphate)
HOBt 1H-benzotriazol-1-ol
HPLC high-performance liquid chromatography
HS-665 3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)
phenol
i.t. intrathecal
JWH-018 (or AM 678) naphthalen-1-yl(1-pentyl-1H-indol-3-yl)
methanone
k’ retention factor (HPLC)
KOR kappa opioid receptor
MOR mu opioid receptor
MsCl methanesulfonyl chloride
NMM 4-methylmorpholine
NMR nuclear magnetic resonance (spectroscopy)
Rf retention factor (TLC)
RVD-hemopressin H-Arg-Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-
Leu-Ser-His-OH
SEM standard error of mean
TEA triethylamine
TFA triﬂuoroacetic acid
D9-THC ()-trans-D9-tetrahydrocannabinol
THF tetrahydrofuran
TLC thin layer chromatography
WIN-55,212-2 (R)-(þ)-[2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-naphthalenylmethanone
mesylate
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rimonabant led to the loss of analgesic effects in hot plate and tail
ﬂick tests [25]. In contrast, bivalent compounds of the MOR agonist
a-oxymorphamine and a rimonabant analogue with oxydiacetic
acid-based spacers were found to exhibit antinociception in tail
ﬂick test without producing tolerance in 24 h [26]. Another
important goal of the combination treatments is to decrease the
effective dose of opioids, especially in the treatment of severe
chronic pains. It could be potentially achieved by combining opioid
agonists with cannabinoid agonists [3,27e30]. In a case study of a
patient with familial Mediterranean fever it was reported that the
administration of D9-tetrahydrocannabinol (D9-THC) reduced the
morphine consumption by about 50% to alleviate chronic pain [27].
In order to target the MOR and CB receptors with a single
compound, bivalent ligands consisting of a MOR and a CB agonist
were designed. In one set the MOR agonist oxycodone [1,31e33],
that is widely used in the treatment of severe pain [34] was applied.
The other set contained the enkephalin-related tetrapeptide Tyr-D-
Ala-Gly-Phe [35e37] as the opioid pharmacophore. Both opioid
agonists were coupled with naphthalen-1-yl(1-pentyl-1H-indol-3-
yl)methanone (JWH-018 or AM 678), a full CB agonist. JWH-018 is
an indole-type synthetic CB receptor agonist that structurally re-
lates to WIN-55,212e2. It exhibits typical cannabinoid pharma-
cology in vivo and has high afﬁnity for both CB receptors
(Ki(CB1)¼ 9.00 nM, Ki(CB2)¼ 2.94 nM) [38e41]. The receptor
binding and signaling properties of the resulting bivalent com-
pounds were investigated and the in vitro active compounds were
tested in vivo after spinal administration for antinociception in a
chronic pain model, which might be clinically relevant.
2. Materials and methods
2.1. General
The purity of all reagents and solvents were analytical or the
highest commercially available grade. Starting materials, buffercomponents, GDP, GTPgS were purchased from Sigma-Aldrich Kft.
(Budapest, Hungary), fatty acid free bovine serum albumin (BSA)
was from Serva (Heidelberg, Germany), DAMGOwas obtained from
Bachem AG (Bubendorf, Switzerland), Ile5,6-deltorphin-2 was pre-
pared in the Laboratory of Chemical Biology (BRC, Hungary),
naloxone was kindly provided by Endo Laboratories (Wilmington,
DE, USA), WIN-55,212e2 was purchased from Tocris Inc. (Bristol,
UK), [35S]GTPgS (s.a. >37 TBq/mmol) was purchased from Hart-
mann Analytic (Braunschweig, Germany). The radioligands [3H]
JWH-018 (s.a. 1.48 TBq/mmol), [3H]WIN-55,212e2 (s.a. 485 GBq/
mmol), [3H]DAMGO (s.a. 1.43 TBq/mmol), [3H]Ile5,6-deltorphin-2
(s.a. 725 GBq/mmol) and [3H]HS-665 (s.a. 1.13 TBq/mmol) were
prepared in the Laboratory of Chemical Biology (BRC, Hungary).
Tritium labeling was carried out in a self-designed vacuum mani-
fold [42] and radioactivity was measured with a Packard Tri-Carb
2100 TR liquid scintillation analyser using Insta Gel scintillation
cocktail of PerkinElmer. Analytical thin layer chromatography (TLC)
was performed on 5 10 cm glass plates precoated with silica gel
60 F254 (Merck, Darmstadt, Germany), spots were visualized with
UV light. Flash chromatography was carried out on silica gel 60
(Sigma Ltd., St. Louis, MO, USA) using the indicated solvents.
Analytical HPLC separations were performed with a Merck-Hitachi
LaChrom system on an Alltech Altima HP C18 (150 4.6mm, 5 mm)
or on a Vydac 218TP54 (250 4.6mm, 5 mm) column using the
indicated gradients of ACN (0.08% (v/v) TFA) (eluent B) in H2O
(0.1%(v/v) TFA) (eluent A) at a ﬂow rate of 1mL/min, and UV
detection at l¼ 216 nmwas applied. Radio-HPLCwas performed on
a Phenomenex Luna C18(2) (150 4.6mm, 5 mm) column using a
Jasco HPLC system equipped with a Packard Radiomatic 505 TR
Flow Scintillation Analyser. 1H and 13C NMR spectra were recorded
on a Bruker Avance 500MHz or on a Varian Mercury 300MHz
spectrometer and chemical shifts (d) are reported in ppm after
calibration to the solvent signals. The assignments are based on 1H,
13C(DEPT), HSQC, HMBC, GQ-COSYand 2D-TOCSYexperiments, and
on the reported assignment of JWH-018 [43]. Molecular weight of
the compounds was determined by ESI-MS analysis on a Finnigan
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2.2. Oxycodone O-carboxymethyloxime (1)
Oxycodone (1 g, 3.17mmol) was dissolved in 250mL of EtOH
then 365mg of 2-(aminooxy)acetic acid hemihydrochloride
(3.32mmol) and 400 mL of pyridine were added. The solution was
stirred at 80 C for 75min then the precipitate was ﬁltered and
dried under vacuum. The crude product was puriﬁed by HPLC on a
Vydac 218TP1010 column (250 10mm, 10 mm) using a linear
gradient of 10/ 50% B in A over 25min at a ﬂow rate of 4mL/min
(l¼ 216 nm) to give 1.14 g (93%) of pure 1 as a white solid. Rf 0.26
(CHCl3eMeOHeNH3(aq) 9:1:0.1); HPLC k’¼ 4.90 (tR¼ 12.4min,
linear gradient of 5/ 30% B in A over 25min, ﬂow rate: 1mL/min,
l¼ 216 nm); 1H NMR (500MHz, MeOD) d 6.88 (d, 1H, J¼ 8.2 Hz, 2-
H), 6.79 (d, 1H, J¼ 8.2 Hz, 1-H), 5.03 (s, 1H, 5-H), 4.54 and 4.53
(2 s, 2 1H, CH2-COOH), 3.85 (s, 3H, OCH3), 3.59 (d,1H, J¼ 6.4 Hz,
9-H), 3.47 (d, 1H, J¼ 19.9 Hz, 10-H), 3.19 (dd, 1H, J¼ 13.0, 4.6 Hz, 16-
H), 3.11 (dd, 1H, J¼ 19.9, 6.4 Hz, 10-H0), 2.93 (s, 3H, NCH3), 2.87 (dd,
1H, J¼ 13.0, 3.9 Hz, 16-H0), 2.72 (ddd, 1H, J¼ 17.3, 7.0, 2.2 Hz, 15-H),
2.62 (m, 2H, 7-H, 15-H0), 1.75 (m, 1H, 7-H0), 1.71 (dd, 1H, J¼ 7.0,
2.6 Hz, 8-H), 1.46 (ddd, 1H, J¼ 14.1, 11.5, 7.0 Hz, 8-H’); 13C NMR
(126MHz, MeOD) d 175.6 (COOH), 156.7 (C-6), 146.7 (C-4), 144.8 (C-
3), 130.1 (C-12), 124.2 (C-11), 121.1 (C-1), 117.7 (C-2), 87.5 (C-5), 72.9
(O-CH2-COOH), 71.2 (C-14), 68.3 (C-9), 57.7 (OCH3), 48.3 (C-16), 47.2
(C-13), 41.7 (NCH3), 30.0 (C-7), 28.9 (C-8), 24.7 (C-10), 18.6 (C-15);
ESI-MS calcd for C20H24N2O6 388.16, found 388.59 [MþH]þ.
2.3. Oxycodone O-(N-(2-(N-Boc-amino)ethyl)carboxamidomethyl)
oxime (2)
Oxime 1 (20mg, 51.5 mmol) and HOBt.H2O (7.9mg, 51.5 mmol)
were dissolved in 1.5mL of DMF and DIC (8 mL, 51.5 mmol) was
added. It was stirred for 5min, then tert-butyl 2-
aminoethylcarbamate hydrochloride (20mg, 102 mmol) and DIEA
(18 mL, 102 mmol) were added to the solution. The mixture was
stirred at 50 C for 16 h then it was evaporated in vacuo. The crude
product was puriﬁed by column chromatography on silica gel 60
with CHCl3eMeOH (8:2) to give 22.2mg (81%) of 2 as yellowish oil.
Rf 0.45 (CHCl3eMeOH 9:1); HPLC k’¼ 4.65 (tR¼ 11.9min, linear
gradient of 10/ 60% B in A over 25min); 1H NMR (500MHz,
CDCl3) d 6.83 (brs, 1H, 2-H), 6.74 (d, 1H, J¼ 8.2 Hz, 1-H), 6.58 (brs,
CONH), 5.88 (brs, 1H, CONH), 5.07 and 5.01 (2 s, 1H, 5-H), [4.68
and 4.58 (2 d, J¼ 16.9 Hz), 4.53 (d, J¼ 16.0 Hz)] (2H, O-CH2-CO),
3.90 (s, 3H, OCH3), 3.71 (m,1H, 9-H), 3.28 (overlapping m, 6H, 100-H,
200-H, 10-H, 16-H), 3.08 (d, 1H, J¼ 18.5 Hz, 10-H0), 2.90 (brs, 4H,
NCH3, 15-H), 2.77 (m, 2H, 7-H, 16-H0), 2.33 (m, 1H, 15-H0), 1.80 (m,
2H, 7-H0, 8-H), 1.48 (m, 1H, 8-H0), 1.40 (s, 9H, C(CH3)3); ESI-MS calcd
for C27H38N4O7 530.27, found 531.30 [MþH]þ.
2.4. Oxycodone O-(N-(6-(N-Boc-amino)hexyl)carboxamidomethyl)
oxime (3)
Prepared as described for 2 but tert-butyl 6-
aminohexylcarbamate (22mg, 102 mmol) was used. The crude
product was puriﬁed by column chromatography on silica gel 60
with CHCl3eMeOH (8:2) to give 23.1mg (77%) of 3 as pale yellow
oil. Rf 0.44 (CHCl3eMeOH 9:1); HPLC k’¼ 6.76 (tR¼ 16.3min, linear
gradient of 10/ 60% B in A over 25min); 1H NMR (500MHz,
CDCl3) d 6.83 (d, 1H, J¼ 8.2 Hz, 2-H), 6.74 (d, 1H, J¼ 8.2 Hz, 1-H),
6.09 (t, 1H, J¼ 5.1 Hz, CONH), 5.05 (s, 1H, 5-H), [4.60 and 4.52 (2 d,
2 1H, J¼ 15.7 Hz, O-CH2-CO), 3.90 (s, 3H, OCH3), 3.85 (m,1H, 9-H),
3.27 (overlapping m, 4H, 100-H, 600-H), 3.08 (m, 3H, 10-H, 10-H0, 16-
H), 2.91 (s, 3H, NCH3), 2.82 (m, 2H, 7-H, 16-H0), 2.71 (brs, 1H, 15-
H), 2.33 (m, 1H, 15-H0), 1.85 (brs, 1H, 8-H), 1.77 (d, 1H, J¼ 9.7 Hz,7-H0), 1.47 (m, 5H, 200-H, 500-H, 8-H0), 1.43 (s, 9H, C(CH3)3), 1.31 (m,
4H, 300-H, 400-H); ESI-MS calcd for C31H46N4O7 586.34, found 587.40
[MþH]þ.
2.5. Oxycodone O-(N-(13-(N-Boc-amino)-4,7,10-trioxatridecyl)
carboxamidomethyl)oxime (4)
Prepared as described for 2 but N-Boc-4,7,10-trioxa-1,13-
tridecanediamine (33mg, 102 mmol) was used. The crude product
was puriﬁed by column chromatography on silica gel 60 with
CHCl3eMeOH (8:2) to give 23.6mg (66%) of 4 as yellowish oil. Rf
0.52 (CHCl3eMeOH 9:1); HPLC k’¼ 4.94 (tR¼ 12.5min, linear
gradient of 5/ 95% B in A over 25min); 1H NMR (500MHz, CDCl3)
d 6.82 (d, 1H, J¼ 8.2 Hz, 2-H), 6.73 (d, 1H, J¼ 8.2 Hz, 1-H), 6.43 (brs,
CONH), 5.06 (s, 1H, 5-H), 5.01 (brs, CONH), 4.58 and 4.51 (2 d,
2 1H, J¼ 15.8 Hz, O-CH2-CO), 3.90 (s, 3H, OCH3), 3.84 (m,1H, 9-H),
(3.61, 3.57, 3.52) (3m, 12H, 300-H, 500-H, 600-H, 800-H, 900-H, 1100-H),
3.43e3.19 (overlapping m, 6H, 100-H, 1300-H, 10-H, 16-H), 3.08 (dd,
1H, J¼ 19.6, 6.0 Hz,10-H0) 2.90 (s, 3H, NCH3), 2.81 (m, 3H, 7-H,15-H,
16-H0), 2.69 (m,1H,15-H0), 1.83 (m,1H, 8-H), 1.74 (m, 5H, 7-H0, 200-H,
1200-H), 1.44 (m, 1H, 8-H0), 1.43 (s, 9H, C(CH3)3); ESI-MS calcd for
C35H54N4O10 690.38, found 691.15 [MþH]þ.
2.6. Oxycodone O-(N-(2-aminoethyl)carboxamidomethyl)oxime (5)
The N-protected oxime 2 (22mg, 41.5 mmol) was dissolved in
2mL of DCM containing 50% (v/v) TFA and it was stirred for
30min at rt. The solution was evaporated in vacuo that yielded the
TFA salt of 5. 21mg (95%); Rf 0.27 (CHCl3eMeOH 9:1); HPLC
k’¼ 3.64 (tR¼ 10.2min, linear gradient of 5/ 30% B in A over
25min); ESI-MS calcd for C22H30N4O5 430.22, found 431.30
[MþH]þ.
2.7. Oxycodone O-(N-(6-aminohexyl)carboxamidomethyl)oxime
(6)
Prepared as described for 5. Yield 22mg (96%); Rf 0.26
(CHCl3eMeOH 9:1); HPLC k’¼ 4.90 (tR¼ 12.4min, linear gradient
of 5/ 95% B in A over 25min); ESI-MS calcd for C26H38N4O5
486.28, found 487.11 [MþH]þ.
2.8. Oxycodone O-(N-(13-amino-4,7,10-trioxatridecyl)
carboxamidomethyl)oxime (7)
Prepared as described for 5. Yield 22.5mg (95%); Rf 0.33
(CHCl3eMeOH 9:1); HPLC k’¼ 4.82 (tR¼ 12.8min, linear gradient
of 5/ 30% B in A over 25min); ESI-MS calcd for C30H46N4O8
590.33, found 591.09 [MþH]þ.
2.9. 6-(1H-indol-1-yl)hexanoic acid (8)
To a stirred solution of indole (1.17 g, 10mmol) in ACN (10mL)
were added triethylamine (1.39mL, 10mmol) and 6-
bromohexanoic acid (1.94 g, 10mmol), then the solution was stir-
red at 80 C for 16 h. The solvent was evaporated in vacuo and the
residue was extracted with water and CHCl3 (3 20mL). The
combined organic phase was washed with brine, and dried over
Na2SO4. After evaporation the crude product was puriﬁed by col-
umn chromatography on silica gel 60 with EtOAcn-hexane 2:1 to
give 1.76 g (77%) of pure 8 as yellow oil. Rf 0.38 (EtOAcen-hexane
2:1); HPLC k’¼ 4.36 (tR¼ 15.0min, linear gradient of 5/ 60% B in
A over 25min); 1H NMR (500MHz, CDCl3) d 7.63 (d, 1H, J¼ 7.9 Hz,
4-H), 7.33 (d, 1H, J¼ 8.2 Hz, 7-H), 7.20 (t, 1H, J¼ 7.6 Hz, 5-H), 7.10 (t,
1H, J¼ 7.6 Hz, 6-H), 7.09 (d, 1H, J¼ 3.2 Hz, 2-H), 6.48 (d, 1H,
J¼ 3.1 Hz, 3-H), 4.13 (t, 2H, J¼ 7.1 Hz,10-H), 2.33 (t, 2H, J¼ 7.4 Hz, 50-
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1.38 (quin, 2H, J¼ 7.7 Hz, 30-H); 13C NMR (126MHz, CDCl3) d 178.2
(COOH), 136.0 (C-7a), 128.7 (C-3a), 127.9 (C-2), 121.5 (C-6), 121.1 (C-
4), 119.4 (C-5), 109.4 (C-7), 101.1 (C-3), 46.3 (C-10), 33.8 (C-50), 30.1
(C-20), 26.6 (C-30), 24.4 (C-40); ESI-MS calcd for C14H17NO2 231.13,
found 231.93 [MþH]þ.
2.10. 6-(3-(1-Naphthoyl)-1H-indol-1-yl)hexanoic acid (9)
To a stirred solution of 8 (1.5 g, 6.49mmol) in 5mL of dry DCM
6.5mL of 1M Et2AlCl in hexane (6.49mmol) was added dropwise. It
was stirred at 0 C for 1 h then 1.2 g of 1-naphthoyl chloride
(6.49mmol) dissolved in 3mL of DCM was added dropwise. The
reaction mixture was stirred at 0 C for 16 h then it was carefully
poured into amixture of ice and 0.1MHCl and it was extractedwith
DCM. The combined organic phase was washed with brine and
dried over Na2SO4. The organic phase was evaporated and the
crude product was puriﬁed by column chromatography on silica gel
60 with (EtOAcn-hexane 1:1) to give 1.05 g (42%) of pure 9 as
yellow oil that became crystalline in a day. Rf 0.26 (EtOAcen-hex-
ane 2:1); HPLC k’¼ 5.07 (tR¼ 17.0min, linear gradient of
20/100% B in A over 25min); 1H NMR (500MHz, CDCl3) d 8.50
(m,1H, 4-H), 8.19 (d,1H, J¼ 8.3 Hz,150-H), 7.98 (d,1H, J¼ 8.2 Hz,110-
H), 7.92 (d, 1H, J¼ 8.1 Hz, 120-H), 7.67 (d, 1H, J¼ 7.0 Hz, 90-H), [7.54
(t, 1H, J¼ 8.2 Hz) and 7.52 (t, 1H, J¼ 8.2 Hz)] (100-H and 130-H), 7.47
(t, 1H, J¼ 7.1 Hz, 140-H), 7.41e7.34 (overlapping m, 4H, 2-H, 5-H, 6-
H, 7-H), 4.08 (t, 2H, J¼ 7.3 Hz,10-H), 2.26 (t, 2H, J¼ 7.4 Hz, 50-H),1.83
(quin, 2H, J¼ 7.4 Hz, 20-H), 1.62 (quin, 2H, J¼ 7.6 Hz, 40-H), 1.31 (m,
2H, 30-H); 13C NMR (126MHz, CDCl3) d 192.5 (3-CO), 181.6 (COOH),
138.9 (C-80), 137.6 (C-2), 136.9 (C-7a), 133.8 (C-11a0), 130.6 (C-15a0),
130.4 (C-110), 128.4 (C-120), 127.0 (C-140), 126.8 (C-3a), 126.5 (C-130),
126.0 (C-90), 125.7 (C-150), 124.7 (C-100), 123.3 (C-6), 122.7 (C-5),
122.2 (C-4), 117.4 (C-3), 110.1 (C-7), 46.4 (C-10), 37.3 (C-50), 29.9 (C-
20), 26.3 (C-30), 25.3 (C-40); ESI-MS calcd for C25H23NO3 385.17,
found 386.03 [MþH]þ.
2.11. Bivalent compound 10
The carboxylic acid 9 (7.4mg, 19 mmol) and HOBt.H2O (2.9mg,
19 mmol) were dissolved in 1.5mL of DMF and DIC (2.9 mL, 19 mmol)
was added. It was stirred for 5min, then 5 (20.7mg, 38 mmol) and
DIEA (6.6 mL, 38 mmol) were added and the solution was stirred at
50 C for 16 h. Then it was evaporated in vacuo and the crude
product was puriﬁed by semipreparative HPLC on a Vydac
218TP1010 column that yielded 12.1mg of 10 (79%) as yellow oil. Rf
0.63 (CHCl3eMeOH 9:1); HPLC k’¼ 5.82 (tR¼ 14.3min, linear
gradient of 10/100% B in A over 25min); 1H NMR (500MHz,
CDCl3) d 1H NMR (CDCl3) d 8.40 (d, 1H, J¼ 6.8 Hz, 40-H), 8.15 (d, 1H,
J¼ 8.4 Hz, 150-H), 7.96 (d, 1H, J¼ 8.1 Hz, 110-H), 7.90 (d, 1H,
J¼ 8.1 Hz, 120-H), 7.65 (d, 1H, J¼ 6.8 Hz, 90-H), 7.52 (t, 1H, J¼ 7.6 Hz,
100-H), 7.50 (t, 1H, J¼ 7.5 Hz, 130-H), 7.45 (t, 1H, J¼ 7.6 Hz, 140-H),
7.41 (s, 1H, 20-H), 7.39 (s, 1H, 70-H), 7.32 (m, 2H, 50-H, 60-H), 6.81 (d,
1H, J¼ 8.2 Hz, 2-H), 6.74 (brs, CONH), 6.72 (d, 1H, J¼ 8.2 Hz, 1-H),
6.43 (brs, CONH), 4.99 (s, 1H, 5-H), 4.57 and 4.47 (2 d, 2 1H,
J¼ 16.1 Hz, O-CH2-CO), 4.08 (t, 2H, J¼ 6.9 Hz, 160-H), 3.85 (s, 3H,
OCH3), 3.73 (brs, 1H, 9-H), 3.26 (2 brs, 5H, 100-H, 200-H, 16-H), 3.21
(d, 1H, J¼ 19.0 Hz, 10-H), 3.00 (d, 1H, J¼ 19.0 Hz, 10-H0), 2.84 (s, 4H,
NCH3,15-H), 2.73 (brs, 2H, 7-H,16-H0), 2.40 (d,1H, J¼ 8.2 Hz,15-H0),
2.09 (t, 2H, J¼ 5.7 Hz, 200-H), 1.81 (quin, 2H, J¼ 7.1 Hz, 170-H), 1.76
(m, 1H, 8-H), 1.65 (d, 1H, J¼ 8.0 Hz, 7-H0), 1.56 (quin, 2H, 6.9 Hz, 190-
H),1.35 (m,1H, 8-H0), 1.27 (m, 2H,180-H); 13C NMR (126MHz, CDCl3)
d 192.3 (Ar-CO),174.3 (200-CONH),170.9 (O-CH2-CONH),156.7 (C-6),
145.9 (C-4),143.8 (C-3), 139.0 (C-80), 138.2 (C-20), 137.2 (C-7a0), 133.9
(C-11a0), 130.9 (C-15a0), 130.2 (C-110), 128.6 (C-12), 128.4 (C-120),
127.1 (C-3a0), 126.9 (C-140), 126.5 (C-130), 126.1 (C-90), 126.0 (C-150),124.8 (C-100), 123.8 (C-60), 123.0 (C-50), 122.9 (C-40), 121.6 (C-11),
120.0 (C-1), 117.6 (C-30), 115.8 (C-2), 110.3 (C-70), 86.9 (C-5), 73.2 (O-
CH2-CO), 70.4 (C-14), 65.7 (C-9), 56.8 (OCH3), 47.3 (C-16), 47.1 (C-
160), 46.2 (C-13), 42.1 (NCH3), 39.8 and 39.6 (C-100, C-200), 36.1 (C-
200), 29.6 (C-170), 29.3 (C-7), 28.6 (C-8), 26.4 (C-180), 25.1 (C-190),
24.1 (C-10), 17.3 (C-15); MALDI-MS calcd for C47H51N5O7 797.38,
found 798.34 [MþH]þ.
2.12. Bivalent compound 11
Prepared as described for 10, but 6 (23mg, 38 mmol) was used.
Yield 11.6mg of 11 (71%) as brown oil. Rf 0.60 (CHCl3eMeOH 9:1);
HPLC k’¼ 6.18 (tR¼ 15.1min, linear gradient of 10/100% B in A
over 25min); 1H NMR (500MHz, CDCl3) d 8.41 (d, 1H, J¼ 7.5 Hz, 40-
H), 8.14 (d, 1H, J¼ 8.3 Hz, 150-H), 7.96 (d, 1H, J¼ 8.2 Hz, 110-H), 7.90
(d, 1H, J¼ 8.1 Hz, 120-H), 7.63 (d, 1H, J¼ 6.6 Hz, 90-H), 7.52 (t, 1H,
J¼ 7.9 Hz, 100-H), 7.50 (t, 1H, J¼ 8.2 Hz, 130-H), 7.44 (t, 1H, J¼ 7.6 Hz,
140-H), 7.38 (overlapping d, 1H, 70-H), 7.37 (s, 1H, 20-H), 7.33 (m, 2H,
50-H, 60-H), 6.81 (d, 1H, J¼ 8.2 Hz, 2-H), 6.72 (d, 1H, J¼ 8.3 Hz, 1-H),
6.26 (brs, 1H, 100-NH), 6.06 (brs, 600-NH), 5.00 (s, 1H, 5-H), 4.58 and
4.50 (2 d, 2 1H, J¼ 15.9 Hz, O-CH2-CO), 4.07 (t, 2H, J¼ 6.8 Hz,
160-H), 3.85 (s, 3H, OCH3), 3.78 (brs, 1H, 9-H), 3.30 (q, 1H, J¼ 6.3 Hz,
100-H), 3.24 (brs, 1H, 16-H), 3.23 (d, 1H, J¼ 19.4 Hz, 10-H), 3.14 (m,
2H, 100-H0, 600-H), 3.03 (d, 1H, J¼ 19.3 Hz, 10-H0), 2.91 (d, 1H,
J¼ 18.7 Hz, 600-H0), 2.84 (s, 3H, NCH3), 2.73 (brs, 2H, 7-H,16-H0), 2.69
(m, 1H, 15-H), 2.60 (m, 1H, 15-H0), 2.11 (t, 2H, J¼ 6.4 Hz, 200-H), 1.80
(quin, 3H, J¼ 7.0 Hz, 170-H, 8-H), 1.68 (d, 1H, J¼ 8.5 Hz, 7-H0), 1.57
(quin, 2H, 6.3 Hz, 190-H), [1.42 (m, 4H) and 1.26 (brs, 4H)] (200-H, 300-
H, 400-H, 500-H), 1.34 (m, 1H, 8-H0), 1.26 (brs, 2H, 180-H); 13C NMR
(126MHz, CDCl3) d 192.4 (Ar-CO), 173.8 (200-CONH), 170.0 (O-CH2-
CONH), 156.8 (C-6), 145.6 (C-4), 143.9 (C-3), 139.0 (C-80), 138.3 (C-
20), 137.2 (C-7a0), 133.9 (C-11a0), 130.8 (C-15a0), 130.2 (C-110), 128.4
(C-120), 128.3 (C-12), 127.1 (C-3a0), 126.9 (C-140), 126.5 (C-130), 126.1
(C-90),126.0 (C-150),124.8 (C-100), 123.9 (C-60),123.1 (C-50),123.0 (C-
40), 121.3 (C-11), 120.0 (C-1), 117.6 (C-30), 116.0 (C-2), 110.2 (C-70),
86.4 (C-5), 73.3 (O-CH2-CO), 70.4 (C-14), 66.0 (C-9), 56.9 (OCH3),
47.6 (C-16), 47.1 (C-160), 46.0 (C-13), 42.0 (NCH3), 39.4 (C-600), 38.7
(C-100), 36.2 (C-200), 29.5 (C-170), (29.2, 28.3, 26.1, 26.0) (C-200, C-300,
C-400, C-500), 29.0 (C-7), 28.4 (C-8), 26.4 (C-180), 25.3 (C-190), 24.0 (C-
10), 17.9 (C-15); MALDI-MS calcd for C51H59N5O7 853.44, found
854.49 [MþH]þ.
2.13. Bivalent compound 12
Prepared as described for 10, but 7 (26.8mg, 38 mmol) was used.
Yield 11.1mg of 12 (61%) as yellow oil. Rf 0.70 (CHCl3eMeOH 9:1);
HPLC k’¼ 6.06 (tR¼ 14.8min, linear gradient of 10/100% B in A
over 25min); 1H NMR (500MHz, CDCl3) d 8.42 (d, 1H, J¼ 6.8 Hz, 40-
H), 8.16 (d, 1H, J¼ 8.3 Hz, 150-H), 7.97 (d, 1H, J¼ 8.1 Hz, 110-H), 7.90
(d, 1H, J¼ 8.1 Hz, 120-H), 7.65 (d, 1H, J¼ 6.6 Hz, 90-H), 7.53 (t, 1H,
J¼ 7.6 Hz, 100-H), 7.51 (t, 1H, J¼ 7.5 Hz, 130-H), 7.45 (t, 1H, J¼ 7.3 Hz,
140-H), 7.40 and 7.39 (2 s, 2 1H, 20-H, 70-H), 7.34 (m, 2H, 50-H, 60-
H), 6.80 (d, 1H, J¼ 8.2 Hz, 2-H), 6.71 (d, 1H, J¼ 8.3 Hz, 1-H), 6.68
(brs, CONH), 6.55 (brs, CONH), 5.01 (s, 1H, 5-H), 4.59 and 4.50
(2 d, 2 1H, J¼ 15.9 Hz, O-CH2-CO), 4.09 (t, 2H, J¼ 6.9 Hz, 160-H),
3.87 (s, 3H, OCH3), 3.77 (brs, 1H, 9-H), 3.58e3.41 (m, 12H, 300-H, 500-
H, 600-H, 800-H, 900-H,1100-H), 3.27 (brs, 4H,100-H,1300-H), 3.26 (brs,1H,
16-H), 3.22 (d, 1H, J¼ 19.1 Hz, 10-H), 3.03 (d, 1H, J¼ 18.6 Hz, 10-H0),
2.86 (s, 3H, NCH3), 2.74 (brs, 2H, 7-H, 16-H0), 2.70 (brs, 1H, 15-H),
2.60 (d, 1H, J¼ 12.0 Hz, 15-H0), 2.12 (t, 2H, J¼ 6.5 Hz, 200-H), 1.81 (m,
3H, 8-H, 170-H), 1.70 (m, 5H, 7-H0, 200-H, 1200-H), 1.59 (quin, 2H,
6.7 Hz, 190-H), 1.37 (brs, 1H, 8-H0), 1.27 (m, 2H, 180-H); 13C NMR
(126MHz, CDCl3) d 192.3 (Ar-CO), 173.8 (200-CONH), 169.9 (O-CH2-
CONH), 156.7 (C-6), 145.7 (C-4), 143.9 (C-3), 139.0 (C-80), 138.2 (C-
20), 137.2 (C-7a0), 133.9 (C-11a0), 130.9 (C-15a0), 130.2 (C-110), 128.4
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90), 126.0 (C-150), 124.8 (C-100), 123.8 (C-60), 123.05 (C-50), 122.97 (C-
40), 121.3 (C-11), 119.9 (C-1), 117.6 (C-30), 116.0 (C-2), 110.2 (C-70),
86.5 (C-5), 73.3 (O-CH2-CO), (70.3, 70.1, 70.0, 69.9, 69.4) (7C, C-14,
C-300, C-500, C-600, C-800, C-900, C-1100), 66.0 (C-9), 57.0 (OCH3), 47.6 (C-
16), 47.1 (C-160), 46.1 (C-13), 42.0 (NCH3), 38.1 and 37.1 (C-100, C-1300),
36.1 (C-200), 30.6 (C-8), 29.6 (C-170), 29.2 (C-7), 28.9 (C-200, C-1200),
26.4 (C-180), 25.2 (C-190), 24.1 (C-10), 17.8 (C-15); MALDI-MS calcd
for C55H67N5O10 957.49, found 958.23 [MþH]þ.
2.14. (1H-Indol-3-yl)(naphthalen-1-yl)methanone (13)
Indole (250mg, 2.13mmol) was dissolved in 5mL of DCM and
1.74mL of Et2AlCl (25% (w/w) in toluene (3.2mmol) was added at
0 C. The mixture was stirred at 0 C for 30min and 1-naphthoyl
chloride (609mg, 3.2mmol dissolved in 8mL of DCM) was added
dropwise to the solution at 0 C, and it was stirred for 16 h. Then the
reaction mixture was quenched with 100mM NaHCO3. The pre-
cipitate was ﬁltered and the ﬁltrate was evaporated in vacuo. The
crude product was puriﬁed by column chromatography on silica gel
60 (n-hexaneeEtOAc 2:1) to give 13 (406mg, 70%) as yellow solid.
Rf 0.44 (n-hexaneeEtOAc 2:1); 1H NMR (300MHz, CDCl3) d 8.73
(brs, 1H, NH indole), 8.50 (d, 1H, J¼ 6.6 Hz, 4-H), 8.17 (d, 1H,
J¼ 8.1 Hz, 150-H), 7.96 (d, 1H, J¼ 8.4 Hz, 110-H), 7.89 (d, 1H,
J¼ 7.5 Hz,120-H), 7.66 (d,1H, J¼ 6.8 Hz, 90-H), 7.53e7.36 (m, 7H,100-
H, 130-H, 140-H, 2-H, 5-H, 6-H, 7-H); 13C NMR (300MHz, CDCl3)
d 138.7, 136.5, 134.9, 133.7, 130.7, 130.1, 128.1, 126.8, 126.3, 125.9,
125.8, 124.5, 124.1, 123.0, 122.7, 119.2, 111.4; ESI-MS calcd for
C19H13NO 271.10, found 272.24 [MþH]þ.
2.15. tert-Butyl 5-bromopentylcarbamate (14)
To a stirred solution of tert-butyl 5-hydroxypentyl-carbamate
(500mg, 2.46mmol) and TEA (498mg, 4.92mmol) in 5mL DCM
at 10 C was added MsCl (338mg, 2.95mmol) dropwise and the
solution was stirred at the same temperature for 5 h. The reaction
was then quenched with water. The organic layer was washed with
water, brine, dried over MgSO4, ﬁltered and evaporated under
reduced pressure to give the desired product as yellow oil (552mg,
80%, Rf 0.5 (EtOAc)) The mesylate was used in the next step without
any further puriﬁcation. Under N2 atmosphere 5-(tert-butox-
ycarbonylamino)pentyl methanesulfonate (350mg, 1.2mmol) was
dissolved in 5mL THF followed by the addition of LiBr (313mg,
3.6mmol) to the solution. The reaction mixture was stirred for 16 h
under reﬂux, then THF was removed under vacuum. The mixture
was diluted with 10mL water and it was extracted with DCM
(3 10mL). The combined organic phase was washed with water
(3 10mL) and brine (3 10mL), dried over MgSO4 and evapo-
rated in vacuo. The product was puriﬁed by column chromatog-
raphy on silica gel 60 (n-hexaneeEtOAc 9:1) to give white
crystalline product (230mg, 72%). Rf 0.6 (n-hexaneeEtOAc 4:1); 1H
NMR (300MHz, CDCl3) d 4.59 (brs, 1H, NH), 3.37 (t, 2H, J¼ 8.4 Hz, 5-
H), 3.09 (q, 2H, J¼ 7.8 Hz, 1-H), 1.84 (quin, 2H, J¼ 7.3 Hz, 4-H),
1.49e1.36 (m, 4H, 2-H, 3-H), 1.40 (s, 9H, CH3); 13C NMR (300MHz,
CDCl3) d 155.9 (CONH), 79.0 (C(CH3)3), 40.2 (C-1), 33.6 (C-5), 32.2
(C-4), 29.2 (CH3), 28.3 (C-2), 25.3 (C-3); ESI-MS calcd for
C10H20BrNO2 265.07, found 266.12 [MþH]þ.
2.16. tert-Butyl (5-(3-(1-naphthoyl)-1H-indol-1-yl)pentyl)
carbamate (15)
To a stirred solution of NaH (60% dispersion in mineral oil,
15.4mg, 0.44mmol) in 5mL of DMF at 0 C was added 13 (100mg,
0.368mmol) in 10mL DMF dropwise and themixturewas stirred at
80 C for 1 h. The reaction mixturewas cooled to 0 C and a solutionof 14 (108mg, 0.41mmol) in 5mL DMF was added dropwise and
stirred at 0 C for 30min, and then stirred for 18 h at rt. Then it was
evaporated and the oily residue was dissolved in EtOAc (50mL).
The organic layer was washed with water (3 50mL) and brine
(3 50mL), dried over Na2SO4 and evaporated in vacuo. The crude
residue was puriﬁed by column chromatography on silica gel 60
(ethyl acetate/hexane 1:2) to yield 15 (142mg, 85%) as orange-red
oil. Rf 0.59 (n-hexaneeEtOAc 2:1); HPLC k’¼ 6.36 (tR¼ 20.6min,
linear gradient of 5/ 95% B in A over 25min); 1H NMR (300MHz,
DMSO‑d6) d 8.29 (d, 1H, J¼ 8.4 Hz, 150-H), 8.07 (d, 1H, J¼ 8.1 Hz, 110-
H), 8.00 (t,1H,140-H), 7.75 (s,1H, 20-H), 7.68e7.49 (m, 5H, 90-H, 70-H,
130-H, 100-H, 120-H), 7.30 (m, 2H, 50-H, 60-H), 6.72 (t, 1H, NH-Boc),
4.17 (t, 2H, J¼ 7.3 Hz, 10-H), 2.81 (q, 2H, 50-H), 1.68 (quin, 2H,
J¼ 7.3 Hz, 20-H), 1.29e1.15 (m, 13H, 40-H, 30-H, 3 CH3); 13C NMR
(300MHz, DMSO‑d6) d 191.3 (3-CO), 155.9 (CONH), 139.8 (C-80),
138.9 (C-2), 137.2 (C-7a), 133.7 (C-11a0), 130.5 (C-15a0), 130.1 (C-110),
128.7 (C-120), 127.1 (C-140), 126.8 (C-3a), 126.7 (C-130), 126.2 (C-90),
125.7 (C-150), 125.4 (C-100), 123.7 (C-6), 122.9 (C-4), 122.1 (C-5),
116.4 (C-3), 111.5 (C-7), 77.7 (C(CH3)3), 46.6 (C-10), 29.5 (C-40), 29.3
(C-20), 28.6 (CH3), 23.7 (C-30); ESI-MS calcd for C29H32N2O3 456.24,
found 457.12 [MþH]þ.
2.17. (1-(5-Aminopentyl)-1H-indol-3-yl)(naphthalen-1-yl)
methanone (16)
The Boc-protected amine 15 (137mg, 0.3mmol) was dissolved
in 2mL DCM containing 50% (v/v) TFA and it was stirred for
30min at rt. The solution was evaporated and the product was
washed with DCM and evaporated in vacuo to give 16 (135mg,
97%); Rf 0.56 (MeOHeAcOH 95:5); HPLC k’¼ 4.22 (tR¼ 11.0min,
linear gradient of 10/100% B in A over 25min); ESI-MS calcd for
C24H24N2O 356.19, found 357.08 [MþH]þ.
2.18. N-(5-(3-(1-Naphthoyl)-1H-indol-1-yl)pentyl)acetamide (17)
The amine 16 (17mg, 36 mmol) dissolved in 1mL of DCM fol-
lowed by the addition of 0.3mL TEA and 0.3mL acetic anhydride.
The mixture was then stirred at rt for 16 h, then it was evaporated
in vacuo. The crude 17 was puriﬁed by column chromatography on
silica gel 60 (EtOAceDCM 9:1) to give 17 (13mg, 91%); Rf 0.54 (n-
hexaneeEtOAc 2:1); HPLC k’¼ 4.70 (tR¼ 16.0min, linear gradient
of 20/100% B in A over 25min); 1H NMR (300MHz, DMSO‑d6)
d 8.31 (d, 1H, 150-H), 8.06 (d, 1H, J¼ 8.1 Hz, 110-H), 8.00 (d, 1H,
J¼ 8.2 Hz,140-H), 7.76 (s, 1H, 20-H), 7.74e7.48 (m, 6H, 90-H, 70-H,130-
H, 100-H, 120-H, NH), 7.30 (m, 2H, 50-H, 60-H), 4.17 (t, 2H, J¼ 7.3 Hz,
10-H), 2.93 (q, 2H, J¼ 5.7 Hz, 50-H), 1.71e1.65 (m, 5H, CH3 and 20-H),
1.32 (quin, 2H, J¼ 7.3 Hz, 40-H), 1.17 (quin, 2H, J¼ 7.4 Hz, 30-H); 13C
NMR (300MHz, DMSO‑d6) d 191.3 (3-CO), 169.3 (CONH), 139.8 (C-
80), 138.9 (C-2), 137.2 (C-7a), 133.7 (C-11a0), 130.5 (C-15a0), 130.1 (C-
110), 128.7 (C-120), 127.1 (C-140), 126.8 (C-3a), 126.7 (C-130), 126.2 (C-
90), 125.7 (C-150), 125.4 (C-100), 123.7 (C-6), 122.9 (C-4), 122.2 (C-5),
116.4 (C-3), 111.5 (C-7), 46.5 (C-10), 38.6 (C-50), 29.6 (C-40), 29.0 (C-
20), 23.9 (CH3), 23.01 (C-30); ESI-MS calcd for C26H26N2O2 398.20,
found 399.02 [MþH]þ.
2.19. Peptide synthesis, general procedure
To an ice-cooled mixture containing N-protected amino acid or
peptide (0.28mmol) in DCM (5mL), EDC.HCl (1.1 equiv.,
0.28mmol), HOBt (1.1 equiv., 0.28mmol), NMM (3.3 equiv.,
0.85mmol), the required protected amino acid (1 equiv.,
0.25mmol) dissolved in DMF (2.5mL) was added. The reaction
mixture was allowed to warm at rt for 16 h and evaporated under
reduced pressure. The residue was then dissolved in EtOAc and
washed with three portions of 5% citric acid, NaHCO3 and brine. The
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under reduced pressure to give the desired product. All ﬁnal Boc-
protected intermediates have been puriﬁed by ﬂash chromatog-
raphy on silica gel 60 and then treated with a mixture of TFA/DCM
(1:1) for 30min at ambient temperature. The ﬁnal products as TFA
salts were lyophilised and then characterized as follows.
2.20. Tyr-D-Ala-Gly-Phe-NH2
It was prepared as described [44].
2.21. Bivalent compound 18
Overall isolated yield 21%; Rf 0.71 (ACNeMeOHeH2O 4:1:1);
HPLC k’¼ 4.43 (tR¼ 15.2min, linear gradient of 20/100% B in A
over 25min); 1H NMR (300MHz, DMSO‑d6) d 9.34 (s, 1H, Tyr OH),
8.57 (d, 1H, J¼ 6.9 Hz, D-Ala NH), 8.28 (d, 1H, J¼ 7.2 Hz, 150-H), 8.20
(t, 1H, Gly NH), 8.08e7.94 (m, 8H, Phe ArH, Tyr NH, Phe NH, 50-NH),
7.74 (s, 1H, 2-H), 7.66e7.44 (m, 5H, 90-H, 100-H, 110-H, 120-H, 130-H),
7.33 (quin, 1H, 140-H), 7.21e7.09 (m, 4H, 4-H, 5-H, 6-H, 7-H), 7.01 (d,
2H, J¼ 8.7 Hz, Tyr ArH), 6.68 (d, 2H, J¼ 8.7 Hz, Tyr ArH), 4.41 (q, 1H,
Phe Ha), 4.28 (quin, 1H, D-Ala Ha), 4.15 (t, 2H, 10-H), 3.95 (q, 1H, Tyr
Ha), 3.61 (dd, 2H, Gly Ha), 2.97e2.67 (m, 6H, Phe Hb, Tyr Hb, 50-H),
1.65 (quin, 2H, 20-H), 1.25 (quin, 2H, 40-H) 1.10e1.02 (m, 5H, 30-H, D-
Ala Hb); ESI-MS calcd for C47H50N6O6 794.38, found 795.63
[MþH]þ.
2.22. Bivalent compound 19
Overall isolated yield 14%; Rf 0.73 (ACNeMeOHeH2O 4:1:1);
HPLC k’¼ 4.24 (tR¼ 14.7min, linear gradient of 20/100% B in A
over 25min); 1H NMR (300MHz, DMSO‑d6) d 9.30 (s, 1H, Tyr OH),
8.49 (d,1H, J¼ 6.9 Hz, D-Ala NH), 8.27 (m, 2H, Gly NH,150-H), 8.18 (t,
1H, Gly NH), 8.07e7.96 (m, 6H, 90-H, 100-H, 110-H, 120-H, 130-H, Tyr
NH, Phe NH), 7.87 (brs, 1H, Tyr NH), 7.75 (s, 1H, 2-H), 7.65e7.48 (m,
5H, 4-H, 5-H, 6-H, 7-H, 50-NH), 7.29 (m,1H,140-H), 7.19e7.13 (m, 5H,
Phe ArH), 6.98 (d, 2H, J¼ 8.7 Hz, Tyr ArH), 6.66 (d, 2H, J¼ 8.7 Hz, Tyr
ArH), 4.47 (q,1H, Phe Ha), 4.27 (quin,1H, D-Ala Ha), 4.16 (t, 2H,10-H),
3.91 (q, 1H, Tyr Ha), 3.56 (d, 4H, Gly Ha), 2.96e2.70 (m, 6H, 50-H, Tyr
Hb, Phe Hb), 1.68 (quin, 2H, 20-H), 1.36 (quin, 2H, 40-H), 1.18 (quin,
2H, 30-H), 1.01 (d, 3H, D-Ala Hb); ESI-MS calcd for C49H53N7O7
851.40, found 852.63 [MþH]þ.
2.23. Bivalent compound 20
Overall isolated yield 25%; Rf 0.68 (ACNeMeOHeH2O 4:1:1);
HPLC k’¼ 6.59 (tR¼ 15.9min, linear gradient of 5/ 95% B in A over
25min); 1H NMR (300MHz, DMSO‑d6) d 9.33 (s, 1H, OH Tyr), 8.55
(d, 1H, D-Ala NH), 8.28 (d, 1H, 150-H), 8.20 (t, 1H, Gly NH), 8.09e7.97
(m, 9H, Phe ArH, Phe NH, b-Ala NH, Tyr NH, 50-NH), 7.77e7.49 (m,
7H, 2-H, 90-H, 100-H, 110-H, 120-H, 130-H, 140-H), 7.34e7.12 (m, 4H, 4-
H, 5-H, 6-H, 7-H), 7.01 (d, 2H, Tyr ArH), 6.68 (d, 2H, Tyr ArH), 4.39
(q, 1H, Phe Ha), 4.29 (quin, 1H, D-Ala Ha), 4.16 (t, 2H, 10-H), 3.95 (q,
1H, Tyr Ha), 3.58 (d, 2H, Gly Ha), 2.93e2.71 (m, 6H, 50-H, Tyr Hb, Phe
Hb), 2.13 (t, 2H, bAla Ha), 1.67 (quin, 2H, 20-H), 1.33 (quin, 2H, 40-H),
1.21e1.15 (m, 4H, b-Ala Hb, 30-H), 1.05 (d, 3H, D-Ala Hb); ESI-MS
calcd for C50H55N7O7 865.42, found 866.14 [MþH]þ.
2.24. Bivalent compound 21
Overall isolated yield 12%; Rf 0.67 (ACNeMeOHeH2O 4:1:1);
HPLC k’¼ 4.27 (tR¼ 14.8min, linear gradient of 20/100% B in A
over 25min); 1H NMR (300MHz, DMSO‑d6) d 9.32 (s, 1H, Tyr OH),
8.54 (d, 1H, D-Ala NH), 8.29 (d, 1H, 150-H), 8.20 (t, 1H, Gly NH),
8.06e8.00 (m, 8H, Phe ArH, Phe NH, Tyr NH, 50-NH), 7.75 (s, 1H, 2-H), 7.63e7.52 (m, 6H, 120-H, 90-H, 100-H, 110-H, 140-H, 130-H),
7.30e7.11 (m, 4H, 4-H, 5-H, 6-H, 7-H), 6.96 (d, 2H, Tyr ArH), 6.69 (d,
2H, Tyr ArH), 4.40 (q, 1H, Phe Ha), 4.29 (quin, 1H, D-Ala Ha), 4.18 (t,
2H, 10-H), 3.96 (q, 1H, Tyr Ha), 3.64 (d, 2H, Gly Ha), 2.94e2.70 (m,
7H, Tyr Hb, Phe Hb, Gaba NH, 50-H), 1.93 (t, 2H, Gaba Ha), 1.69 (quin,
2H, J¼ 7.3 Hz, 20-H), 1.49 (quin, 2H, Gaba Hb), 1.33 (quin, 2H, 40-H),
1.21 (m, 4H, 30-H, Gaba Hg), 1.06 (d, 3H, D-Ala Hb); ESI-MS calcd for
C51H57N7O7 879.43, found 880.23 [MþH]þ.
2.25. 1-Pentyl-1H-indole (22)
To a stirred solution of indole (1.17 g, 10mmol) in ACN (10mL)
were added TEA (1.01 g, 10mmol) and 1-iodopentane (1.98 g,
10mmol), then the solution was stirred at 80 C for 16 h. The sol-
vent was evaporated in vacuo and the residue was extracted with
water and CHCl3 (3 20mL). The combined organic phase was
washed with brine, and dried over Na2SO4. After evaporation the
crude product was puriﬁed by column chromatography (n-hex-
aneEtOAc 95:5) to give 1.40 g (75%) of pure 22 as an oil. Rf 0.70 (n-
hexaneEtOAc 95:5); HPLC k’¼ 4.30 (tR¼ 11.7min, linear gradient
of 50/100% B in A over 25min); 1H NMR (500MHz, CDCl3) d 7.63
(d, 1H, J¼ 7.9 Hz, 4-H), 7.35 (d, 1H, J¼ 8.1 Hz, 7-H), 7.20 (t, 1H,
J¼ 7.6 Hz, 5-H), 7.10 (d, 1H, J¼ 3.1 Hz, 2-H), 7.09 (t, 1H, J¼ 8.0 Hz, 6-
H), 6.49 (d, 1H, J¼ 3.1 Hz, 3-H), 4.12 (t, 2H, J¼ 7.2 Hz, 10-H), 1.85
(quin, 2H, J¼ 7.2 Hz, 20-H), 1.33 (m, 4H, 30-H, 40-H), 0.89 (t, 3H,
J¼ 7.0 Hz, CH3); 13C NMR (126MHz, CDCl3) d 136.1 (C-7a), 128.7 (C-
3a), 127.9 (C-2), 121.4 (C-6), 121.1 (C-4), 119.3 (C-5), 109.5 (C-7),
100.9 (C-3), 46.6 (C-10), 30.1 (C-20), 29.3 (C-30), 22.5 (C-40), 14.1
(CH3); ESI-MS calcd for C13H17N 187.14, found 188.02 [MþH]þ.
2.26. 5-Bromo-1-pentyl-1H-indole (23)
1.96 g of 5-bromo-1H-indole (10mmol) was dissolved in 20mL
of DMF containing 1.6 g of powdered NaOH, then 1-iodopentane
(1.98 g, 10mmol) was added dropwise. After 4 h stirring at
ambient temperature the mixture was ﬁltered and the ﬁltrate was
evaporated in vacuo. The resulting oil was dissolved in CHCl3 and
extracted with water. The organic phase was washed with brine
and dried over Na2SO4. The crude product was puriﬁed by column
chromatography (n-hexaneeEtOAc 95:5) to give 1.75 g (66%) of
pure 23 as an oil. Rf 0.62 (n-hexaneeEtOAc 95:5); HPLC k’¼ 6.18
(tR¼ 15.8min, linear gradient of 50/100% B in A over 25min); 1H
NMR (CDCl3) 1H NMR (500MHz, CDCl3) d 7.74 (d, 1H, J¼ 1.6 Hz, 4-
H), 7.27 (dd, 1H, J¼ 8.8 Hz, 1.6 Hz, 7-H), 7.21 (d, 1H, J¼ 8.8 Hz, 6-H),
7.09 (d, 1H, J¼ 3.0 Hz, 2-H), 6.42 (d, 1H, J¼ 2.9 Hz, 3-H), 4.08 (t, 2H,
J¼ 7.2 Hz,10-H),1.82 (quin, 2H, J¼ 7.3 Hz, 20-H),1.31 (m, 4H, 30-H, 40-
H), 0.88 (t, 3H, J¼ 7.1 Hz, CH3); 13C NMR (126MHz, CDCl3) d 134.8
(C-7a), 130.3 (C-3a), 129.1 (C-2), 124.3 (C-6), 123.5 (C-4), 112.6 (C-5),
111.0 (C-7), 100.6 (C-3), 46.7 (C-10), 30.1 (C-20), 29.2 (C-30), 22.4 (C-
40), 14.1 (CH3); ESI-MS calcd for C13H16BrN 265.05, found 266.18
[MþH]þ.
2.27. Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone (24)
To a stirred solution of 22 (281mg, 1.5mmol) in 10mL of dry
DCM at 0 C was added dropwise 1.5mL of 1M Et2AlCl in hexane
(1.5mmol). The solution was stirred at 0 C for 1 h followed by the
dropwise addition of 286mg of 1-naphthoyl chloride (1.5mmol) in
3mL DCM. The reactionmixturewas stirred at 0 C for 16 h then the
solution was poured carefully into a mixture of ice and 0.1M HCl
and it was extracted with DCM. The combined organic phase was
evaporated and the residue was dissolved in diethyl ether that was
washed with 15% K2CO3. The organic phase was evaporated and the
crude product was puriﬁed by column chromatography (n-hex-
aneEtOAc 4:1) to give 368mg (72%) of pure 24 as an oil. Rf 0.44 (n-
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of 50/ 95% B in A over 25min); 1H NMR (500MHz, CDCl3) d 8.49
(m,1H, 4-H), 8.19 (d,1H, J¼ 8.4 Hz,150-H), 7.97 (d,1H, J¼ 8.2 Hz,110-
H), 7.91 (d, 1H, J¼ 8.1 Hz, 120-H), 7.66 (d, 1H, J¼ 6.9 Hz, 90-H), [7.53
(t, 1H, J¼ 7.5 Hz) and 7.52 (t, 1H, J¼ 7.1 Hz)] (100-H and 130-H), 7.47
(t, 1H, J¼ 7.6 Hz, 140-H), 7.41e7.35 (overlapping m, 4H, 2-H, 5-H, 6-
H, 7-H), 4.07 (t, 2H, J¼ 7.3 Hz, 10-H), 1.81 (quin, 2H, J¼ 7.4 Hz, 20-H),
1.28 (m, 4H, 30-H, 40-H), 0.85 (t, 3H, J¼ 7.0 Hz, CH3); 13C NMR
(126MHz, CDCl3) d 192.2 (CO),139.3 (C-80), 138.1 (C-2), 137.2 (C-7a),
133.9 (C-11a0), 131.0 (C-15a0), 130.1 (C-110), 128.3 (C-120), 127.2 (C-
3a), 126.9 (C-140), 126.4 (C-130), 126.2 (C-90), 126.0 (C-150), 124.7 (C-
100), 123.7 (C-6), 123.1 (C-5), 123.0 (C-4), 117.7 (C-3), 110.1 (C-7), 47.3
(C-10), 29.6 (C-20), 29.1 (C-30), 22.3 (C-40), 14.0 (CH3); ESI-MS calcd
for C24H23NO 341.18, found 341.95 [MþH]þ.
2.28. Naphthalen-1-yl(5-bromo-1-pentyl-1H-indol-3-yl)
methanone (25)
Prepared as described for 24, but starting from 23 (400mg,
1.5mmol). The crude product was puriﬁed by column chromatog-
raphy (n-hexaneeEtOAc 4:1) to give 517mg (82%) of pure 25 as an
oil. Rf 0.40 (n-hexaneeEtOAc 4:1); HPLC k’¼ 7.62 (tR¼ 18.1min,
linear gradient of 50/100% B in A over 25min); 1H NMR
(500MHz, CDCl3) d 8.71 (d, 1H, J¼ 1.6 Hz, 4-H), 8.17 (d, 1H,
J¼ 8.3 Hz, 150-H), 7.98 (d, 1H, J¼ 8.2 Hz, 110-H), 7.92 (d, 1H,
J¼ 8.0 Hz, 120-H), 7.65 (dd, 1H, J¼ 6.9 Hz, 0.7 Hz, 90-H), [7.53 (t, 1H,
J¼ 7.6 Hz) and 7.52 (t,1H, J¼ 6.7 Hz)] (100-H and 130-H), 7.48 (dt,1H,
J¼ 7.7 Hz, 1.2 Hz, 140-H), 7.45 (dd, 1H, J¼ 8.7 Hz, 1.8 Hz, 6-H), 7.32 (s,
1H, 2-H), 7.26 (d, 1H, J¼ 8.4 Hz, 7-H), 4.04 (t, 2H, J¼ 7.2 Hz, 10-H),
1.79 (quin, 2H, J¼ 7.4 Hz, 20-H), 1.26 (m, 4H, 30-H, 40-H), 0.85 (t, 3H,
J¼ 7.1 Hz, CH3); 13C NMR (126MHz, CDCl3) d 191.9 (CO), 138.8 (C-
80), 138.5 (C-2), 135.9 (C-7a), 133.9 (C-11a), 130.9 (C-15a), 130.4 (C-
110), 128.7 (C-3a), 128.4 (C-120), 127.0 (C-140), 126.8 (C-130), 126.5 (C-
90), 126.0 (2C, C-150, C-6), 125.8 (C-4), 124.7 (C-100), 117.2 (C-3), 116.8
(C-5), 111.5 (C-7), 47.5 (C-10), 29.6 (C-20), 29.0 (C-30), 22.3 (C-40), 14.0
(CH3); ESI-MS calcd for C24H22BrNO 419.09, found 420.14 [MþH]þ.
2.29. [3H]Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone (26)
Tritium labeling was performed with 3.6mg of 25 (8.5 mmol)
dissolved in 0.6mL of EtOAc in the presence of 3mg of Pd/C (10%
Pd) catalyst and triethylamine (1.5 mL, 10.7 mmol). The reaction
mixture was degassed prior to tritium reduction by two freeze-
thaw cycles, and then it was stirred under 0.25 bar of tritium gas
for 4 h at rt. The unreacted tritium gas was then adsorbed onto
pyrophoric uranium and the catalyst was ﬁltered off with a syringe
ﬁlter. The ﬁltrate was evaporated in vacuo and the labile tritium
was removed by repeated evaporations from EtOH solution. Finally
7.03 GBq of [3H]JWH-018 was isolated as a white solid that was
puriﬁed by HPLC on a Phenomenex Luna C18(2) column (k’¼ 8.08
(tR¼ 19.1min), linear gradient of 50/ 95% B in A over 25min). The
speciﬁc activity was determined by using an HPLC peak area cali-
bration curve recorded with 24 and it was found to be 1.48 TBq/
mmol. The tritium labeled JWH-018 was dissolved in EtOH (37
MBq/mL) and stored under liquid nitrogen.
2.30. Tritium labeling of 11
2mL 1.15mg/mL MeOH solution of 9 (6 mmol) was mixed with
250 mL 3% (v/v) ICl inMeOH (14.2 mmol) and the solutionwas stirred
at ambient temperature for 60min. Then 50mg/mL Na2S2O5 in
water was added until decolorization, and the iodo derivative of 9
was puriﬁed by semipreparative HPLC on a Phenomenex Luna
C18(2) stationary phase. The resulting 1.6mg (55%) of iodo-9 was
dissolved in 400 mL DMFand 3mg of Pd/BaSO4 (10% Pd) catalyst andtriethylamine (1.4 mL,10 mmol) were added and tritium labeling was
performed as described for [3H]JWH-018 to give 64 MBq of [3H]9
with a speciﬁc activity of 64 GBq/mmol. Finally, 37 MBq of [3H]9
and HOBt.H2O (0.3mg, 1.9 mmol) were dissolved in 150 mL of DMF
and DIC (0.3 mL, 1.9 mmol) was added. It was stirred for 5min, then 6
(2.1mg, 2.9 mmol) and DIEA (1.4 mL, 8 mmol) were added and the
solution was stirred at rt for 16 h. It was then evaporated in vacuo
and the crude product was puriﬁed byHPLC on a Phenomenex Luna
C18(2) column that yielded 5.5 MBq [3H]11 (15%). S.a. 64 GBq/
mmol; HPLC k’¼ 5.48 (tR¼ 13.6min, linear gradient of 20/100%
B in A over 25min).
2.31. Tritium labeling of 19
To a solution of 19 (970 mL 1mg/mL MeOH, 1 mmol) 1.8mg of
IPy2BF4 (4.8 mmol) and 4.4 mL of HBF4 in Et2O were added and the
reaction mixture was stirred for 1 h at rt under nitrogen. The re-
action was quenched with a solution of Na2S2O5 in water and the
iodo derivative of 19 was puriﬁed by HPLC on a Phenomenex Luna
C18(2) stationary phase yielding 0.8mg (60%) of diiodo-19. It was
dissolved in 400 mL DMF and 2.5mg of Pd/BaSO4 (10% Pd) catalyst
and triethylamine (0.8 mL, 5.6 mmol) were added and tritium la-
beling was performed as described for [3H]JWH-018 to give 80 MBq
of [3H]19 with a speciﬁc activity of 185 GBq/mmol. HPLC k’¼ 6.78
(tR¼ 16.3min, linear gradient of 5/ 95% B in A over 25min).
2.32. Preparation of brain membrane homogenates
Wistar rats and guinea pigs were locally bred and handled ac-
cording to the EU Directive 2010/63/EU and to the Regulations on
Animal Protection (40/2013. (II. 14.) Korm. r.) of Hungary. Crude
membrane fractions were prepared from the brain without cere-
bellum. Brains were quickly removed from the euthanized animals
and directly put in ice-cold 50mM Tris-HCl (pH 7.4) buffer. The
collected tissue was then homogenized in 30 vol (v/w) of ice-cold
buffer with a Braun Teﬂon-glass homogenizer at the highest rpm.
The homogenate was centrifuged at 20 000g for 25min and the
resulting pellet was suspended in the same volume of cold buffer
followed by incubation at 37 C for 30min to remove endogenous
ligands. After centrifugation the pellets were taken up in ﬁve vol-
umes of 50mM Tris-HCl (pH 7.4) buffer containing 0.32M sucrose
and stored in aliquots at 80 C. Prior to the experiment, aliquots
were thawed and centrifuged at 20 000g for 25min and the
pellets were resuspended in 50mM Tris-HCl (pH 7.4), homogenized
with a Dounce followed by the determination of the protein con-
tent by the method of Bradford. The membrane suspensions were
immediately used either in radioligand binding experiments or in
[35S]GTPgS functional assays.
2.33. Radioligand binding assays
Binding experiments of [3H]JWH-018 were performed at 30 C
for 60min in 50mM Tris-HCl binding buffer (pH 7.4) containing
2.5mM EGTA, 5mM MgCl2 and 0.5mg/mL fatty acid free BSA in
plastic tubes in a total assay volume of 1mL that contained
0.3e0.5mg/mL membrane protein. Association time course of [3H]
JWH-018 binding was obtained by incubating 0.6 nM [3H]JWH-018
with rat brain membrane (0.45mg/mL protein) at 30 C for various
periods of time (0e90min) in the absence or presence of 10 mM
JWH-018 to assess speciﬁc binding. Dissociation time course of [3H]
JWH-018 was obtained by incubating 0.6 nM [3H]JWH-018 with rat
brain membrane (0.45mg/mL protein) at 30 C for 60min, then
dissociation was initiated by the addition of 10 mM JWH-018 after
different periods of incubation time. The kinetic equilibrium
dissociation constant Kd for [3H]JWH-018 in rat brain membrane
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ation rate constant, ka is the association rate constant calculated as
ka¼ (kobs-kd)/[[3H]JWH-018], kobs is the observed pseudo-ﬁrst or-
der rate constant. Saturation binding experiments were performed
by measuring the speciﬁc binding of [3H]JWH-018 (0.5e35 nM) to
rat brain membranes to determine the equilibrium dissociation
constant (Kd) and the maximal number of binding sites (Bmax). The
speciﬁc binding was measured in the presence of 10 mM JWH-018.
Competition binding experiments were carried out by incu-
bating brain membranes with opioid or cannabinoid receptor
speciﬁc tritiated radioligands in the presence of increasing con-
centrations (1011e105M) of various competing unlabeled li-
gands. MOR competition experiments were performed at 25 C for
60min with 2 nM [3H]DAMGO (Kd¼ 0.5 nM), DOR competition
experiments were performed at 35 C for 45min with 3 nM [3H]
Ile5,6-deltorphin-2 (Kd¼ 2.0 nM) and KOR competition experi-
ments were performed at 25 C for 30min with 1 nM [3H]HS-665
(Kd¼ 0.64 nM) in 50mM Tris-HCl binding buffer (pH 7.4) using rat
brain (MOR, DOR) or guinea pig brain membrane homogenate
(KOR). Non-speciﬁc binding was determined in the presence of
10 mM naloxone (MOR, DOR) or HS-665 (KOR). CB receptor binding
experiments were performed at 30 C for 60min on rat brain
membrane homogenates with 0.6 nM [3H]JWH-018 (Kd¼ 6.5 nM)
or with 1.5 nM [3H]WIN-55,212e2 (Kd¼ 10.1 nM). Non-speciﬁc
binding was determined in the presence of 10 mM JWH-018 or
WIN-55,212e2. The competition experiments were terminated by
diluting the suspensions with ice-cold wash buffer (50mM Tris-
HCl, 2.5mM EGTA, 5mM MgCl2, 0.5% fatty acid free BSA, pH 7.4
for cannabinoid binding, or 50mM Tris-HCl, pH 7.4 for opioid
binding) followed by rapid washing and rapid ﬁltration through
Whatman GF/B or GF/C (MOR, KOR) glass ﬁber ﬁlters (Whatman
Ltd, Maidstone, England) presoaked with 0.1% polyethyleneimine
(only for CB receptor binding). Filtration was performed with a 24-
well Brandel Cell Harvester (Gaithersburg, MD, USA). Filters were
air-dried and immersed into Ultima Gold MV scintillation cocktail
and then radioactivity was measured with a TRI-CARB 2100 TR
liquid scintillation analyser (Packard).
2.34. Ligand stimulated [35S]GTPgS binding assay
Rat brain membranes (30 mg protein/tube) were incubated with
0.05 nM [35S]GTPgS (PerkinElmer) and 1010e105M unlabeled
ligands in the presence of 30 mM GDP, 100mM NaCl, 3mM MgCl2
and 1mM EGTA in 50mM Tris-HCl buffer (pH 7.4) for 60min at
30 C. Basal [35S]GTPgS binding was measured in the absence of
ligands and set as 100%. Nonspeciﬁc binding was determined by the
addition of 10 mM unlabeled GTPgS and subtracted from total
binding. Incubation, ﬁltration and radioactivity measurement of
the samples were carried out as described above.
2.35. Cell culture and permeability assay
Primary rat brain endothelial cells, pericytes and astroglia cells
were isolated and cultured according to the method described in
our previous studies [45,46]. To induce BBB characteristics the
isolated cells were co-cultured with the help of 12-well tissue
culture inserts (Transwell, polycarbonate membrane, 3 mm pore
size, Corning Costar, USA). After two days of co-culture brain
endothelial cells became conﬂuent and 550 nM hydrocortisone
(Sigma) was added to the culture medium and one day before the
experiment cells were treated with CPT-cAMP (250mM, Sigma)
and RO 201724 (17.5mM; Sigma) for 24 h to tighten junctions and
elevate transendothelial resistance [47]. Permeability tests on the
co-cultured BBB model were performed when transendothelial
electrical resistance values expressed to the surface area of theinserts reached 123.8± 12.9 Ucm2, n¼ 16. The resistance of cell-
free inserts was subtracted from the measured data. During the
permeability assay the culture mediumwas changed with the same
as used in the growth period, but it also contained 10% serum.
Compounds [3H]11 and [3H]19 were applied in the upper
compartment in a ﬁnal concentration of 0.25 and 0.75 mM. Com-
pound permeability was measured from the A-B (from blood to
brain) direction. After 15, 30 and 60min samples were collected
both from the upper and lower compartments and the transport of
[3H]11 and [3H]19 was determined by measuring the radioactivity
using a TRI-CARB 2100 TR liquid scintillation analyser (Packard).
Flux of the compounds across coated, cell-free inserts was also
measured. Endothelial permeability coefﬁcients (Pe) were calcu-
lated from clearance values of [3H]11 and [3H]19 as described
previously [47].
2.36. Hot plate test
Thermal nociception in the hot plate test was assessed with a
commercially available apparatus consisting of a metal plate
25 25 cm (Ugo Basile, Italy) heated to a constant temperature of
55.0± 0.1 C, on which a plastic cylinder (20 cm diameter, 18 cm
high) was placed. The time of latency (s) was recorded from the
moment the animal was placed in the cylinder on the hot plate
until it licked its paws or jumped; the cut-off time was 60 s. The
baseline was calculated as the mean of three readings recorded
before testing at intervals of 15min. The time course of latency was
then determined at 15, 30, 45, 60, 90 and 120min after compound
treatment. Data were analysed as time-course curves of the per-
centage of maximum effect (%MPE¼ (post drug latency e baseline
latency)/(cut-off time e baseline latency) 100). CD-1 male mice
(Harlan, Italy) weighing 25 g were used for the hot plate test. The
research protocol was approved by the Service for Biotechnology
and Animal Welfare of the Istituto Superiore di Sanita and autho-
rized by the Italian Ministry of Health, according to Legislative
Decree 26/14, which implemented the EU Directive 2010/63/EU on
the protection of laboratory animals in Italy. Bivalent compounds 11
and 19were injected intravenously (i.v.) at the dose of 10mg/kg in a
volume of 10mL/kg. The control animals were injected i.v. with the
vehicle of the compounds (physiological saline containing 5%
DMSO, 10mL/kg).
2.37. Nociceptive test in rats at spinal level
The procedures involved in the animal surgery and testing were
approved by the Institutional Animal Care Committee of the Uni-
versity of Szeged, Faculty of Medicine. Surgical procedures
including intrathecal (i.t.) catheterization and the monosodium
iodoacetate (MIA)-induced inﬂammation are described in Sup-
porting Information. Mechanical allodynia (von Frey test) was
determined using a dynamic plantar aesthesiometer (Ugobasile,
Comerio, Italy). Prior to baseline testing, each rat was habituated to
a testing box with a wiremesh grid ﬂoor for 20min. Straight metal
ﬁlament was used for the measurements that exerts an increasing
upward force at a constant rate (6.25 g/s) with a maximum cut-off
force of 50 g. The ﬁlament was placed under the plantar surface of
the hind paw. Measurement was stopped when the paw was
withdrawn, and the results were expressed as paw withdrawal
thresholds in grams. The pain thresholds were registered before the
i.t. drug injections (baseline at 0min) and then in every 15min for
90min. The parent drugs (oxycodone (20 mg), JWH-018 (20 mg), Tyr-
D-Ala-Gly-Phe-NH2 (7 mg)) and the bivalent compounds 11 (20 mg)
and 19 (20 mg) were injected over 120 s in a volume of 10 mL, fol-
lowed by 8 mL ﬂush of physiological saline within 60 s. The control
animals were injected with the vehicle of the compounds
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analysed on the MIA-injected hind paws, since none of the treat-
ments inﬂuenced the pain threshold at the contralateral side.
Paw withdrawal thresholds on the inﬂamed side were trans-
formed to % maximum possible effect (%MPE) by the following
formula: %MPE¼ [(observed threshold e baseline threshold)/(50 e
baseline threshold)] 100. It was calculated for the early
(15e45min) and late phase (60e90min) after drug administration.
Therefore, 100% MPE means perfect relief of allodynia (equivalent
to a cut-off value of 50 g for all measurements), while 0% MPE
means that the observed threshold is equivalent to the baseline
value.
2.38. Data analysis
The direct saturation isotherms were determined to obtain the
equilibrium dissociation constant (Kd) and the receptor density
(Bmax). In competition binding studies, the inhibitory constants (Ki)
were calculated from the inﬂexion points of the displacement
curves using nonlinear least-square curve ﬁtting option and the
Cheng-Prusoff equation as Ki¼ EC50/(1 þ [ligand]/Kd). In [35S]
GTPgS binding studies, data were expressed as the percentage
stimulation of the speciﬁc [35S]GTPgS binding over the basal ac-
tivity. Each experiment was performed in triplicate and analysed
with the sigmoid dose-response curve ﬁtting option to obtain po-
tency (ED50) and efﬁcacy (Emax). Statistical comparison of Emax and
EC50 values were performed by one-way ANOVA followed by the
Bonferroni's multiple comparison test (***P < 0.001; **P< 0.01);
Emax values of 11 and 19 in the presence of 10 mM naloxone were
compared to the basal activity by unpaired Student's t-test,
#P< 0.05).
The time-course data sets of the hot plate test and the von Frey
tests were examined by two-way ANOVA. The signiﬁcance of dif-
ferences between the experimental and control groups was calcu-
lated by using the Fisher LSD test for post hoc comparison (P< 0.05
was considered signiﬁcant). All data and curves were analysed by
the GraphPad Prism 5.0 Software, San Diego, CA, USA.
3. Results and discussion
The bivalent compounds were prepared in a convergent way.
The MOR and CB agonists were conjugated via short spacers of
different length (4e15 atoms) and polarity (Scheme 1). Oxycodone
and JWH-018 were modiﬁed at the 6-oxo and at the N-pentyl
groups, respectively, to obtain the key intermediates. In the case of
the peptidic compounds the C-terminal carboxyl function of the
peptide acids was used for the conjugation. Condensation of oxy-
codone with 2-(aminooxy)acetic acid in EtOH resulted in the linker
conjugated O-carboxymethyl ketoxime 1. Due to the a-effect the
ketoximes are stable at physiological pH [48,49], therefore the
bivalent ligands are probably stable against hydrolysis. Then the
carboxymethyl group of 1was activated as an O-benztriazolyl ester
that was used for the N-acylation of the mono-protected diamine
spacers N-Boc-ethylenediamine, N-Boc-1,6-diaminohexane and N-
Boc-4,7,10-trioxa-1,13-tridecanediamine. The ﬁnal acidolytic
removal of the Boc protecting group resulted in the amines 5e7.
JWH-018 was functionalized by introducing a terminal carboxyl
group to the N-pentyl substituent of the indole ring (Scheme 1).
This modiﬁcation does not affect the aromatic groups of JWH-018
that are responsible for aromatic interactions with the CB re-
ceptors [50]. Furthermore, the introduction of heteroatoms to the
alkyl group may be tolerated by CB1 receptors as in the case of the
morpholino group of WIN-55,212e2 [51,52]. The carboxyl deriva-
tive of JWH-018 (9) was prepared in a way analogous to that re-
ported by Huffman et al. [50] The N-alkylation of indole wasachieved with 6-bromohexanoic acid, then 8 was selectively acyl-
ated at position 3 with 1-naphthoyl chloride in the presence of
Et2AlCl. Finally, 9 was activated as an O-benztriazolyl ester and it
was used for the N-acylation of the amines 5e7 resulting in the
bivalent compounds 10e12.
The peptidic compounds 18e21 were prepared also in a
convergent way (Scheme 2). Glycine, 3-aminopropanoic acid or 4-
aminobutanoic acid were used as spacers between the opioid and
cannabinoid pharmacophores. Indole was regioselectively acylated
with 1-naphthoyl chloride and the resulting 3-(a-naphthoyl)-
indole (13) was N-alkylated with N-Boc-5-bromopentane-1-amine
(14). Acidolytic deprotection of the carbamate 15 resulted in the
JWH-018 derivative 16 with a terminal amine in the N-pentyl
group. The N-acetylation of 16 with Ac2O resulted in the control
compound 17. The elongation of 16with the opioid peptide or with
a spacer amino acid followed by the opioid peptide were achieved
in stepwise Boc/tBu solution phase peptide synthesis using EDC and
HOBt as coupling agents.
3.1. Preparation and validation of [3H]JWH-018
The in vitro characterization of the bivalent compounds in
radioligand displacement studies required appropriate opioid and
cannabinoid radioligands. The most commonly used CB radio-
ligands in heterologous competition binding experiments are [3H]
CP-55,940, [3H]HU-243, [3H]WIN-55,212e2, [3H]SR-141716A
(rimonabant), [3H]SR-144528 and [3H]Sch225336 [53]. The struc-
tural diversity of the CB receptor ligands [54] and the presence of
allosteric site on the CB receptors [55] prompted us to prepare a
novel radioligand relevant for the investigation of the CB receptor
binding afﬁnities of the JWH-018 containing bivalent compounds.
JWH-018 was labeled with tritium as outlined in Scheme 3 and the
resulting radioligand was validated in vitro. N-Alkylation of 5-
bromoindole with 1-iodopentane was achieved in the presence of
triethylamine followed by acylationwith 1-naphthoyl chloride that
resulted in the brominated precursor 25. Then 25 was dehalo-
genated with tritium gas under heterogeneous catalytic conditions
and [3H]JWH-018 (26) was obtained with a speciﬁc activity of 1.48
TBq/mmol. In a similar way, JWH-018 (24) was also prepared for the
radioligand binding experiments.
Before its application in radioligand competition assays, [3H]
JWH-018 was characterized in various in vitro receptor binding
experiments. Association and dissociation binding experiments
were performed to characterize the interaction of [3H]JWH-018
with membrane receptors using rat brain membrane homogenate
that contains both CB1 and CB2 receptors [56e59]. Association
binding experiments were carried out in the presence of 0.6 nM
[3H]JWH-018 at 30 C and they revealed speciﬁc binding of [3H]
JWH-018 to rat brain membranes (Fig. 1A). At this temperature the
speciﬁc binding determined in the presence of 10 mM 24 reached
steady-state after 40min, and it remained stable up to 90min, the
longest incubation time investigated (not shown). The speciﬁc
binding was found to be 65% of the total binding at 0.6 nM radio-
ligand concentration under equilibrium conditions. Analyzing the
association curve provided an observed pseudo-ﬁrst order rate
constant (kobs) of 0.124± 0.01 min1. In the dissociation experi-
ments, rat brain membranes were incubated with 0.6 nM of [3H]
JWH-018 at 30 C for 60min and dissociation of the
ligandereceptor complex was initiated by the addition of 10 mM
24 at different incubation periods (Fig. 1B). It was found that 60% of
the radioligand dissociated from the membranes. Dissociation
proceeded with a monophasic kinetics and it resulted in a disso-
ciation rate constant (kd) of 0.105± 0.01 min1. The equilibrium
dissociation constant (Kd) calculated from the kinetic data was
3.4 nM under our experimental conditions. Saturation binding
Scheme 1. Preparation of oxycodone e JWH-018 bivalent compounds.
Reagents and conditions: a) EtOH, pyridine, 80 C, 75min, 93%; b) HOBt, DIC, DIEA, DMF, 50 C, 16 h, 81% (2), 77% (3), 66% (4); c) TFA/DCM (1:1), rt, 30min, 95% (5), 96% (6), 95% (7);
d) 6-bromohexanoic acid, TEA, ACN, 80 C, 16 h, 77% (8); e) 1-naphthoyl chloride, Et2AlCl, DCM, 0 C, 16 h, 42% (9); f) HOBt, DIC, DIEA, DMF, 50 C, 16 h, 79% (10), 71% (11), 61% (12).
Scheme 2. Preparation of peptide e JWH-018 bivalent compounds.
Reagents and conditions: a) 1-Naphthoyl chloride, Et2AlCl, DCM, 0 C, 16 h, 70%; b) MsCl, TEA, DCM, 10 C, 5 h; c) LiBr, THF, reﬂux, 16 h, 72% (14); d) NaH, DMF, 80 C, 18 h, 85%; e)
TFA/DCM (1:1), rt, 30min, 97%; f) Ac2O, TEA, DCM, rt, 16 h, 91% (17), or Boc stepwise peptide synthesis: EDC, HOBt.H2O, NMM, DMF, DCM, and deprotection with TFA/DCM (1:1), rt,
30min; overall yields 21% (18), 14% (19), 25% (20), 12% (21).
Scheme 3. Tritium labeling of JWH-018.
Reagent and conditions: a) (22) 1-iodopentane, TEA, ACN, 80 C, 16 h, 75%, (23) 1-iodopentane, NaOH, DMF, rt, 4 h, 66%; b) Et2AlCl, 1-naphthoyl chloride, DCM, 0 C, 16 h, 72% (24),
82% (25); c) 3H2(g), Pd/C, EtOAc, TEA, rt, 4 h.
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values. The radioligand was incubated with rat brain membranes at
increasing concentrations (0e35 nM) in the absence or presence of
24. The speciﬁc binding of [3H]JWH-018 was found to be saturableand of high afﬁnity in the nanomolar range (Fig. 1C). A single-site
binding was calculated from the non-linear ﬁtting of the speciﬁc
binding data and resulted in an apparent Kd value of 6.5± 1.22 nM
and a high receptor density (Bmax) of 1120± 89 fmol/mg protein.
Fig. 1. Binding of [3H]JWH-018 to rat whole brain membrane homogenates (0.45mg/mL protein). (A) Association and (B) dissociation time courses of [3H]JWH-018 at 30 C; (C)
saturation isotherm of speciﬁc CB receptor binding of [3H]JWH-018 at 30 C for 60min incubation. Data are means ± SEM (n 3).
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brain membrane homogenate with high densities and it displayed
speciﬁc binding to a receptor protein, the binding site of [3H]JWH-
018 was further investigated in competition experiments using
selective and non-selective cannabinoid ligands. The displacement
curves are summarized in Fig. 2 and the calculated inhibitory
constants (Ki) are summarized in the table of Fig. 2. In homologous
displacement experiments the full agonist JWH-018 exhibited a Ki
value of 3.4± 0.80 nM. WIN-55,212e2, another full agonist canna-
binoid ligand displayed high afﬁnity to the JWH-018 binding sites,
while the partial agonist D9-THC competed for the JWH-018 bind-
ing sites with 11-times lower afﬁnity. The CB2 receptor selective,
inverse agonist AM 630 was found to be effective in displacing [3H]
JWH-018 fromCB2 receptors. Further experiments revealed that the
CB1 receptor selective antagonist/inverse agonist rimonabant and
the structurally very similar CB1 selective antagonist/inverseFig. 2. Characterization of JWH-018 binding sites in competition binding experiments in ra
binding of [3H]JWH-018 in the presence of unlabeled cannabinoid or opioid ligands. (D) The
deltorphin-2 and [3H]HS-665, respectively, in the presence of JWH-018 (ﬁlled symbols) or i
mean percentage of speciﬁc binding± SEM (n 3). Table shows the calculated inhibitory
Kd¼ 6.5 nM was obtained from the saturation experiment, data are means ± SEM, n 3.agonist AM 251 were less effective in displacing [3H]JWH-018 from
CB1 receptors on rat brain membrane homogenate. AM 251 dis-
placed 80% of the radioligand from JWH-018 binding sites, while
the CB2 selective inverse agonist AM 630 displaced approximately
70% of [3H]JWH-018 from CB2 receptors on rat brain membrane
homogenate. Compound 25 was also investigated in heterologous
displacement studies, because beside to be a precursor for tritium
labeling it is a potentially bioactive JWH-018 derivative substituted
at position 5 with bromine. It exhibited good CB receptor afﬁnity in
displacing [3H]JWH-018 with a Ki value of 59± 3.3 nM. Interest-
ingly, the 5-bromo-substituted intermediate 25 exhibited receptor
afﬁnity similar to that of rimonabant, AM 630 and AM 251.
Furthermore, the results show that JWH-018 is a non-selective full
agonist in the low nanomolar range with a CB1/CB2 receptor
selectivity ratio of 3 (Ki(AM 251)¼ 69± 9.1 nM)/Ki(AM
630)¼ 23± 19 nM) that is similar to other reported data [39]. In ourt or guinea pig ([3H]HS-665) whole brain membrane homogenates. (AeC) The speciﬁc
speciﬁc binding of the MOR, DOR and KOR speciﬁc radioligands [3H]DAMGO, [3H]Ile5,6-
n the presence of the corresponding unlabeled opioid ligand (open symbols). Data are
constants against [3H]JWH-018. Ki values were as Ki¼ EC50/(1 þ [ligand]/Kd), where
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competed for [3H]JWH-018 binding sites with the following order
of potency: JWH-018>WIN-55,212e2> AM 630> rimona-
bant> 25> AM 251>D9-THC> hemopressin(1e9).
Next, competition binding experiments were performed to
compare the ability of the endogenous peptide cannabinoid RVD-
hemopressin and its derivatives hemopressins(1e7) and (1e9) to
inhibit the binding of [3H]JWH-018 in rat brain membrane ho-
mogenate. It was found that neither the N- and C-terminally
truncated hemopressin(1e7) [60], nor the CB1 negative and CB2
receptor positive allosteric modulator, RVD-hemopressin [61,62]
could displace the bound radioligand. Only the nonapeptid CB1
inverse agonist/antagonist hemopressin(1-9) [63] was able to
compete with [3H]JWH-018, with an apparently high inhibitory
constant of 2793± 4.1 nM, however, hemopressin(1e9) only
partially (c.a. 40%) displaced [3H]JWH-018. These results indicated
that the allosteric binding site of the peptidic ligands is different
from that of the non-peptidic cannabinoid agonists/inverse ago-
nists, and that JWH-018 probably bound to the CB receptors at the
orthosteric binding site.
It was also important to investigate whether [3H]JWH-018 in-
teracts with the opioid receptors because this radioligand was
prepared to characterize the CB receptor binding of the opioid e
cannabinoid bivalent ligands. The effects of the opioid ligands
morphine, naloxone and endomorphins-1 and -2 on the speciﬁc
binding of [3H]JWH-018 were measured in the presence of
increasing concentration of the opioids. It was found that none of
them decreased the speciﬁc binding of [3H]JWH-018 even at a
concentration of 10 mM, meaning that [3H]JWH-018 did not bind to
the opioid receptors (Fig. 2C). Finally, competition binding experi-
ments were carried out to evaluate the ability of JWH-018 to inhibit
speciﬁc binding of the m-, d- and k-opioid receptor (MOR, DOR and
KOR) selective radioligands [3H]DAMGO, [3H]Ile5,6-deltorphin-2
and [3H]HS-665 [64], respectively (Fig. 2D). For KOR binding the
guinea pig brain was used because it contains KORs in higher
density than the rat brain. It was found that JWH-018 did not
exhibited any binding afﬁnity to the MOR, DOR and KOR when
compared to the homologue displacements with DAMGO, Ile5,6-
deltorphin-2 or HS-665, respectively.
3.2. Receptor binding properties of the synthetic compounds
In order to assess the effects of the structural changes of the
monomeric ligands on the biological activity, and to evaluate the
bivalent compounds for afﬁnity and selectivity, the novel synthetic
compounds were subjected to radioligand binding assays. Dis-
placements of the MOR selective radioligand [3H]DAMGO, the DOR
selective [3H]Ile5,6-deltorphin-2, the KOR selective [3H]HS-665 and
the cannabinoid radioligands [3H]JWH-018 and [3H]WIN-55,212-2
by the synthetic compounds were investigated in rat or guinea pig
brain membrane homogenates. It was found that the modiﬁcation
of oxycodone at position 6 with O-carboxymethyl oxime (1)
resulted in a 2.7-fold loss of MOR afﬁnity, a 4-fold increased afﬁnity
for the DOR and loss of KOR afﬁnity (Figure S1, Table 1). The MOR
selectivity of oxycodone over DOR was reduced by the introduction
of the linker group in 1 as the Kid/Kim ratio decreased from 55 to 5.
The introduction of a terminal carboxyl function to the pentyl chain
of JWH-018 (9) decreased the CB receptor afﬁnity 70-fold. The
introduction of the ethylenediamine (5) and the 1,6-
diaminohexane spacers (6) resulted in 2-fold and 5-fold loss of
MOR afﬁnity, respectively, while the incorporation of the O-,O0-
bis(3-aminopropyl)-diethyleneglycol spacer (7) resulted in an 8-
fold loss of MOR afﬁnity as compared to the parent compound
oxycodone. The bivalent compounds 10e12 exhibited good afﬁnity
to the MOR that was only 2e4-fold lower than the MOR afﬁnity ofoxycodone. The selectivity of 10e12 for the MOR over DOR was
15e19, while their MOR selectivity over KOR was found to be 9e10.
In competition binding experiments the capabilities of the bivalent
compounds 10e12 to displace [3H]JWH-018 and [3H]WIN-
55,212e2 were investigated, and it was found that they displaced
40e70% of the speciﬁc bound radioligands [3H]JWH-018 or [3H]
WIN-55,212e2. The bivalent compound 10 exhibited the highest CB
receptor afﬁnity against [3H]WIN-55,212e2, however 11 displaced
[3H]JWH-018 most efﬁciently.
Next, the peptidic compounds were evaluated for afﬁnity and
selectivity by radioligand displacement assays (Figure S2, Table 2).
The opioid pharmacophore Tyr-D-Ala-Gly-Phe-NH2 exhibited high
afﬁnity to the MOR (Ki¼ 0.8 nM), 130-times weaker afﬁnity to the
DOR and 210-times weaker afﬁnity to the KOR, and it had no af-
ﬁnity to the CB receptors. The introduction of a terminal amino
group into the pentyl chain of JWH-018 (16) led to decreased af-
ﬁnity to the [3H]JWH-018 or [3H]WIN-55,212-2 labeled binding
sites. However, N-acetylation of 16 diminished the positively
charged functional group and the CB receptor afﬁnity of 17 was
found to be higher (Ki¼ 145 nM) than that of 16. When 16 was N-
acylated with Tyr-D-Ala-Gly-Phe-OH or with its C-terminally
extended derivatives, the resulting bivalent compounds 18e21
exhibited moderate change in MOR, DOR and KOR afﬁnity. The
binding afﬁnity of 19 and 21 for KOR was 2e3 times higher than
that of the Tyr-D-Ala-Gly-Phe-NH2. In [3H]JWH-018 and [3H]WIN-
55,212-2 displacement experiments 19 exhibited the highest af-
ﬁnity to the CB receptors among the peptidic bivalent compounds
(Ki¼ 251 and 317 nM, respectively), and 19was able to decrease the
[3H]JWH-018 and [3H]WIN-55,212-2 speciﬁc binding by about
45e50%. In contrast, the CB receptor afﬁnity of 18, 20 and 21
decreased signiﬁcantly.
In the next step the signaling properties of the bivalent com-
pounds were investigated in ligand stimulated [35S]GTPgS binding
experiments in rat brain membrane homogenate (Figure S3,
Tables 1 and 2). This tissue preparation abundantly contains both
MOR and CB receptors, therefore it is an appropriate model to
investigate the [35S]GTPgS binding stimulation capability of the
MOR and CB agonists and their derivatives [65,66]. The oxime 1
exhibited lower potency than oxycodone, and signiﬁcant reduction
of the stimulatory effect was observed. Coupling of the spacers to 1
decreased the efﬁcacy, and the partial opioid agonist oxycodone
became weaker partial agonists/neutral antagonists. The tetra-
peptide H-Tyr-D-Ala-Gly-Phe-NH2 increased the G-protein basal
activity with a maximum efﬁcacy of 157% and with a potency of
191 nM. The full agonist JWH-018 efﬁciently stimulated the G-
proteins, demonstrated low potency (69 nM) and high stimulatory
activity (163%). The introduction of the carboxyl function in 9
changed the full agonist to a weak inverse agonist. The amine 16
acted as an antagonist on CB receptors, since it did not stimulate G-
proteins but displayed a considerable CB receptor afﬁnity. The N-
acetylated compound 17 reduced [35S]GTPgS speciﬁc binding
signiﬁcantly by nearly 20% as compared to the basal activity level,
indicating an inverse agonistic effect. The weak inverse agonistic
effect of 17 might be mediated through CB receptors, since it
showed a relatively good afﬁnity to the [3H]JWH-018 binding site.
The bivalent compounds 10 and 12 did not induce signiﬁcant
changes in basal [35S]GTPgS binding, however these compounds
displayed noticeable MOR and CB receptor afﬁnity. In contrast, 11
exhibited high G-protein stimulatory effect (Emax¼ 147± 3.8%,
EC50¼ 215± 4.5 nM) demonstrating the agonist character of 11.
To explore the activation of MOR and/or CB1/CB2 receptor-
mediated signaling induced by 11, the G-protein activation was
investigated in the absence or presence of 10 mM naloxone, 10 mM
rimonabant or 10 mM AM 630 in rat brain membrane homogenate
(Fig. 3). The stimulatory effect of 10 mM 11 (Emax¼ 147± 4.0%,
Table 1
Inhibitory constant values and signaling properties of oxycodone and JWH-018 derivatives.
compd. Ki (nM) Emax (%) EC50 (nM)
[3H]DAMGO [3H]Ile5,6-deltorphin-2 [3H]HS-665 Kid/Kim Kik/Kim [3H]JWH-018 [3H]WIN-55,212-2
oxycodone 8.9± 0.4 487± 36 325± 32 55 37 >10000 >10000 135 ± 4.6 51± 2.5
JWH-018 >10000 >10000 >10000 e e 3.4± 0.8 2.9± 0.4 163 ± 3.1 69± 10
1 24± 0.2 110± 14 >10000 5 e n.d. n.d. 109 ± 3.2 225± 27
5 17± 0.9 533± 33 471± 44 31 28 n.d. n.d. 113 ± 2.1 450± 11
6 41± 3.6 659± 14 380± 43 16 10 n.d. n.d. 111 ± 2.5 305± 14
7 74± 3.0 757± 55 503± 50 10 7 n.d. n.d. 112 ± 7.1 200± 55
9 n.d. n.d. n.d. e e 247± 48 205± 28 81 ± 4.7 4225± 148
10 33± 4.0 623± 43 337± 40 19 10 255± 47 9.3± 1.8 100 ± 1.7 n.r.
11 18± 5.0 263± 15 172± 19 15 10 34± 8 12± 3.5 147 ± 3.8 215± 4.5
12 20± 1.0 386± 23 186± 37 19 9 183± 32 78± 23 99 ± 1.2 n.r.
Ki values were obtained from the displacement curves shown in Figure S1, n.d. not determined; The Emax and EC50 values were calculated from the dose-response curves of
Figure S3, n.r.: not relevant. Data are means± SEM, n 3.
Table 2
Inhibitory constant values and signaling properties of peptidic compounds.
compd. Ki (nM) Emax (%) EC50 (nM)
[3H]DAMGO [3H]Ile5,6-deltorphin-2 [3H]HS-665 Kid/Kim Kik/Kim [3H]JWH-018 [3H]WIN-55,212-2
Tyr-D-Ala-Gly-Phe-NH2 0.8± 0.1 107± 19 173± 15 134 216 >10000 >10000 157± 3.9 191± 7
JWH-018 >10000 >10000 >10000 e e 3.4± 0.8 2.9± 0.4 163± 3.1 69 ± 10
16 n.d. n.d. n.d. e e 190± 17 269± 21 102± 3.5 n.r.
17 n.d. n.d. n.d. e e 145± 13 149± 18 83± 5.6 2154± 100
18 50± 2.7 214± 2.0 231± 35 4 5 1013± 45 823± 62 110± 3.8 1801± 102
19 2.1± 0.3 134± 12 63 ± 13 64 30 251± 18 317± 47 160± 1.9 114± 10
20 48± 5.1 190± 33 151± 25 4 3 919± 48 1216± 102 114± 1.6 18 ± 6
21 20± 3.5 92± 25 50 ± 15 5 3 928± 45 1042± 28 125± 1.5 60 ± 10
Ki values were obtained from the displacement curves shown in Figure S2, n.d. not determined; The Emax and EC50 values were calculated from the dose-response curves of
Figure S3, n.r.: not relevant. Data are means± SEM, n 3.
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naloxone [67] (10 mM) (Emax¼ 112± 2.1%, EC50¼ 397± 34 nM). But
naloxone did not reduce the G-protein stimulatory effect to theFig. 3. Opioid and cannabinoid receptor-mediated effects of 11 and 19 on G-protein activatio
relative speciﬁc binding of [35S]GTPgS with the increasing concentrations (1010e105M) of
630. Data are mean percentage of speciﬁc binding± SEM (n¼ 3e5) over the basal activity. T
values are listed. Statistical comparison of Emax and EC50 were performed by one-way ANO
signiﬁcant difference (unpaired Student's t-test, P< 0.05) in the Emax of 11 or 19 in the prebasal level, and the residual activity suggested that 11 could acti-
vate the CB receptors as well. The CB1 antagonist/inverse agonist
rimonabant (10 mM) slightly antagonized the G-protein stimulatoryn in [35S]GTPgS binding assays in rat brain membrane homogenates. Figures represent
11 or 19 in the absence or presence of 10 mM naloxone, 10 mM rimonabant or 10 mM AM
he calculated maximal G-protein stimulation efﬁcacy (Emax) and ligand potency (EC50)
VA followed by the Bonferroni's multiple comparison test (***, P< 0.001). # indicates
sence of 10 mM naloxone compared to the basal activity. n.r. not relevant.
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antagonist/inverse agonist AM 630 (10 mM) had greater antago-
nistic effect (Emax¼ 122± 2.7%, EC50¼ 340± 7.5 nM). In order to
decrease the stimulatory effect of 11 to the basal level, the copre-
sence of naloxone, rimonabant and AM 630 was required.
The peptidic bivalent compounds 18, 20 and 21 exhibited
signiﬁcantly decreased capability of G-protein activation, but 19
exhibited signaling with a maximum efﬁcacy of 160% that was
similar to that of the parent opioid and cannabinoid compounds.
The binding afﬁnity of 19 to the opioid receptors remained nearly
the same as the parent tetrapeptide amide or 24. The stimulatory
effect of 10 mM 19 (Emax¼ 160± 1.9%, EC50¼112± 7.5 nM) was
partially reduced by the opioid antagonist naloxone [67]
(Emax¼ 121± 2.5%, EC50¼1473± 118 nM), and the residual activity
of 19 indicated CB receptor activation (Fig. 3). In contrast to 11, the
CB2 antagonist/inverse agonist.
AM 630 exerted weak antagonistic effect to 19
(Emax¼ 148± 3.0%, EC50¼ 671± 12 nM), however, the CB1 antago-
nist/inverse agonist rimonabant could antagonize more efﬁciently
the G-protein activation effect of 19 (Emax¼ 125± 1.9%,
EC50¼ 378± 20 nM). The stimulatory effect of 19 decreased to the
basal level in the copresence of naloxone, rimonabant and AM 630.
Taken together, these interactions indicated both an opioid and a CB
receptor dependent agonist effect of 11 and 19.
Because the bivalent compounds 10 and 12 with noticeable
MOR and CB receptor afﬁnity did not induce signiﬁcant changes in
basal [35S]GTPgS binding, their antagonist effect was investigated in
details. In control experiments the G-protein stimulatory agonist
effect of oxycodone was antagonized by the opioid antagonist
naloxone, and that of JWH-018 was antagonized by the co-addition
of the CB1 selective rimonabant and the CB2 selective AM 630. It
was found that the maximum agonist effects of oxycodone, Tyr-D-
Ala-Gly-Phe-NH2, JWH-018, 11 and 19 were reduced to the basal
level by compounds 10 and 12 as well (Fig. 4). These data demon-
strated that compounds 10 and 12 acted as antagonists of the MOR
and CB receptors.
3.3. Permeability of 11 and 19 through the brain endothelium
In order to evaluate whether the agonist bivalent compounds 11
and 19 can effectively target central or peripheral opioid and CB
receptors, the permeability of [3H]11 and [3H]19 through brain
endothelial cells was measured using awell characterized triple co-
culture blood-brain barrier (BBB) model [45,46]. The required
tritium labeled bivalent compounds were prepared from iodinated
precursor compounds. Compound 9 was iodinated with iodine
monochloride in MeOH then it was reduced with tritium gas. The
amine 6 was then N-acylated with [3H]9 under the conditions
outlined in Scheme 1 that yielded [3H]11. In the case of 19, bis(-
pyridine)iodonium(I) tetraﬂuoroborate [68] was used to prepare
the iodo-derivative of 19 that was reduced with tritium gas to
obtain [3H]19. In the in vitro BBB permeability measurement [3H]11
and [3H]19 were applied in 0.25 and 0.75 mM concentrations and
their ﬂuxes in the blood to brain direction was measured. Similar
endothelial permeability coefﬁcients were calculated
(2e3 106 cm/s) for both molecules at both donor concentrations
(Fig. 5). This value is not signiﬁcantly different from the perme-
ability coefﬁcient of ﬂuorescein, a hydrophilic reference molecule
with a limited permeability to the brain. The penetration of 11 and
19was ﬁfteen times higher across empty inserts indicating that the
membrane of the inserts was permeable for the molecules. These
experiments indicated the limited penetration of the bivalent
compounds 11 and 19 via the BBB, thus, an additional test wasperformed using a pain model reﬂecting supraspinal anti-
nociception as the hot plate test.
3.4. Hot plate test
The hot plate test in mice could help to examine whether
compounds cross the BBB after peripheral administration and act at
the receptors located in the central nervous system. For that com-
pounds 11 and 19were administered i.v. at a dose of 10mg/kg, and
the effects on the nociceptive threshold were recorded from 15 to
120min after the injection. The bivalent compounds 11 and 19
slightly increased the thermal latencies after i.v. administration as
compared to the vehicle-treated animals, however, the size of the
effect was not signiﬁcant (Fig. 6). These ﬁndings conﬁrmed the
results of the in vitro study on endothelium permeability, thus,
intrathecal administration was applied during in vivo experiments.
3.5. In vivo evaluation of selected bivalent compounds
The antiallodynic effects of 11 and 19 at spinal level were
measured in a chronic osteoarthritis pain model and were
compared to those of the parent compounds oxycodone, Tyr-D-Ala-
Gly-Phe-NH2 and JWH-018. Osteoarthritis was induced by injecting
sodium iodoacetate into the tibiodorsal joint of one of the hind legs
of rats, and after a 7-day period mechanical allodynia was
measured on the inﬂamed paw in every 15min for 90min. It had
consistently been shown that sodium iodoacetate caused severe
end-stage cartilage destruction resulting in prolonged
osteoarthritis-like joint pain which can be treated with classical
antinociceptive drugs [69e71]. The percentage maximum possible
effect (%MPE) was calculated as the percentage difference between
the measured response and the baseline response, divided by the
difference between the maximum response and the baseline
response [72]. To reveal the duration of the effects of the com-
pounds two phases - the mean values up to 45min as early phase,
and between 60 and 90min, as the late phase - were analysed. All
compounds were applied intrathecally in the same dose (20 mg),
except Tyr-D-Ala-Gly-Phe-NH2, that was administered in lower
dose (7 mg) because higher dose of the peptide led to rigidity in the
animals. The applied doses did not cause visible motor impair-
ments but no detailed behavioral tests were performed to reveal
the subtle side effects of these ligands in this respect. These treat-
ments did not inﬂuence the mechanosensitivity of the non-
inﬂamed side (mean paw withdrawal force for the baseline, early
and late phases: 44± 0.8 g, 41± 1.2 g and 42± 0.9 g, respectively;
see supplementary Table S2), therefore, the results were analysed
only on the iodoacetate-injected paws. The bivalent compounds 11
and 19, and all the control compounds had antiallodynic activity
during the early phase as they signiﬁcantly increased the %MPE
compared to the vehicle treatment (Fig. 7). Regarding the late
phase, the antiallodynic effect of oxycodone declined. The short
duration of the oxycodone-induced antinociception was in agree-
ment with the ﬁndings of Lemberg et al. [73] However, the bivalent
derivatives still produced signiﬁcant effect, that was similar to the
late phase activity of JWH-018. The antiallodynic effects of 11 and
19 were similar to those of oxycodone and JWH-018, and the post
hoc analysis did not show any signiﬁcant differences between the
drug-treated groups. However, considering the nmol doses of the
applied compounds (the molecular weights of 11 and 19 are ca.
twice of the parent ligands; Table S3), Tyr-D-Ala-Gly-Phe-NH2
showed the highest efﬁcacy that was followed by 11 and 19, and
ﬁnally by oxycodone, while JWH-018 showed the lowest efﬁcacy.
Thus, the possible advantage of 11 and 19 might be that they can
Fig. 4. The antagonist effect of 10 and 12 in agonist induced [35S]GTPgS binding assays in rat brain membrane homogenates. Figures represent relative speciﬁc binding of [35S]GTPgS
with the increasing concentrations (1010e105M) of oxycodone, Tyr-D-Ala-Gly-Phe-NH2, JWH-018, 11 and 19 in the absence (ﬁlled symbols) or in the presence (open symbols) of
10 mM of naloxone, rimonabant, AM 630, 10 or 12. Data are mean percentage of speciﬁc binding ± SEM (n 3) over the basal activity (100%). The calculated parameters are listed in
the Supplementary Table S1.
Fig. 5. Evaluation of the ﬂux of compound 11 and 19 across an in vitro BBB model
consisting of primary rat brain endothelial cells, pericytes and astrocytes. Permeability
of sodium ﬂuorescein (SF) is also given as reference. Pe: permeability coefﬁcient, data
are means ± SD, n¼ 4.
Fig. 6. Time-course effects of i.v. administered bivalent compounds in the hot plate
test. Data are means ± SEM, n¼ 6/group.
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concentration.4. Conclusions
The involvement of the MOR and CB receptors in pain man-
agement is well documented and numerous studies report the
synergistic interaction of the opioid and cannabinoid agonists [3].The interaction of the opioid and cannabinoid receptors are hy-
pothesized to undergo at signal transduction level or cannabinoids
may trigger the release of endogenous opioid peptides or the
endocannabinoid system may be altered by opioids [74]. Direct
interaction between the MOR and CB GPCRs may also be a possible
molecular mechanisms underlying the interactions of these sys-
tems [29]. Multitargeting approaches can be applied to exploit
these beneﬁcial interactions, especially in the treatment of chronic
pain, because parallel or independent interaction of a bivalent
compound, i.e. consisting of two covalently linked
Fig. 7. Time-course effects of i.t. administered selected compounds. Data are
means ± SEM, *P < 0.05, **P < 0.01 and ***P< 0.001 vs the vehicle-treated group,
n¼ 6e8/group.
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[75]. Furthermore, bivalent compounds may interact with pre-
dimerized GPCRs in a cooperative manner that can result in
increased afﬁnity of the bivalent ligands relative to the individual
binding of the monovalent components. This way the pharmaco-
kinetics and pharmacodynamics of the single drugs with substan-
tially different absorption and partition properties will be the same,
and a treatment method where the amount of the opioid compo-
nent is subtherapeutic as compared to the administration without
the cannabinoid can be applied.
The strategy of combining GPCR ligands with various spacers to
obtain multitargeting ligands is widely investigated with various
success [76,77]. In our work JWH-018, a synthetic full agonist of CB
receptors was covalently coupled with the semisynthetic opioid
agonist oxycodone or with the enkephalin-related tetrapeptide
agonist Tyr-D-Ala-Gly-Phe via spacers of different length and hy-
drophobicity. The structural diversity of the CB receptor ligands
[78] and the presence of allosteric sites on the CB receptors
prompted us to prepare and validate [3H]JWH-018 as an appro-
priate radioligand competitor of the bivalent compounds in in vitro
experiments. In radioligand binding assays 11 and 19were found to
be able to bind to both the MOR and CB receptors with substantial
afﬁnity. These bivalent compounds exhibited agonist-induced G-
protein activation with high efﬁcacy, and it was also found that the
agonist effects of 11 and 19weremediated via both theMOR and CB
receptors. Compound 11 preferred mainly MOR and CB2, whereas
compound 19 preferred MOR and CB1 receptor mediated in-
teractions, that is in agreement with the role of all these receptors
in the spinal mechanisms of pain relief [9,66,79e82]. In contrast,10
and 12 were found to be antagonists at both the MOR and CB re-
ceptors and they could antagonize the agonist effects of 11 and 19
in vitro. At spinal level the bivalent compounds 11 and 19 were
equieffective with the parent drugs at 20 mg dose in a chronic
osteoarthritis pain model in rats. Because MOR and CB receptor
agonists can be effectively applied in the treatment of chronic pain
including neuropathic pain, these ﬁndings can help to develop
multitargeting antinociceptive drugs featured with opioid and
cannabinoid agonist character in a single molecule.
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